WO1995009249A1 - Oral vaccination of mammals - Google Patents
Oral vaccination of mammals Download PDFInfo
- Publication number
- WO1995009249A1 WO1995009249A1 PCT/US1994/011112 US9411112W WO9509249A1 WO 1995009249 A1 WO1995009249 A1 WO 1995009249A1 US 9411112 W US9411112 W US 9411112W WO 9509249 A1 WO9509249 A1 WO 9509249A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rabies
- pathogen
- amino acid
- protein
- isolated
- Prior art date
Links
- 241000124008 Mammalia Species 0.000 title claims abstract description 34
- 238000002255 vaccination Methods 0.000 title description 10
- 206010037742 Rabies Diseases 0.000 claims abstract description 171
- 244000052769 pathogen Species 0.000 claims abstract description 106
- 230000001717 pathogenic effect Effects 0.000 claims abstract description 104
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 101
- 108010046722 Thrombospondin 1 Proteins 0.000 claims abstract description 98
- 102100036034 Thrombospondin-1 Human genes 0.000 claims abstract description 98
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 49
- 239000000427 antigen Substances 0.000 claims abstract description 44
- 102000036639 antigens Human genes 0.000 claims abstract description 44
- 108091007433 antigens Proteins 0.000 claims abstract description 44
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 43
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 38
- 229960005486 vaccine Drugs 0.000 claims abstract description 37
- 208000015181 infectious disease Diseases 0.000 claims abstract description 31
- 230000003053 immunization Effects 0.000 claims abstract description 17
- 230000002223 anti-pathogen Effects 0.000 claims abstract description 14
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 11
- 229960003127 rabies vaccine Drugs 0.000 claims abstract description 10
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 88
- 150000001413 amino acids Chemical class 0.000 claims description 67
- 241000701447 unidentified baculovirus Species 0.000 claims description 25
- 239000000203 mixture Substances 0.000 claims description 21
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 241000282414 Homo sapiens Species 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 3
- 235000013305 food Nutrition 0.000 claims description 3
- 241000282330 Procyon lotor Species 0.000 claims description 2
- 108091006027 G proteins Proteins 0.000 description 120
- 108091000058 GTP-Binding Proteins 0.000 description 120
- 102000030782 GTP binding Human genes 0.000 description 117
- 108090000623 proteins and genes Proteins 0.000 description 67
- 210000004027 cell Anatomy 0.000 description 57
- 102000004169 proteins and genes Human genes 0.000 description 46
- 241000700605 Viruses Species 0.000 description 37
- 241000711798 Rabies lyssavirus Species 0.000 description 31
- 241000725303 Human immunodeficiency virus Species 0.000 description 25
- 238000012217 deletion Methods 0.000 description 21
- 230000037430 deletion Effects 0.000 description 21
- 241000282335 Procyon Species 0.000 description 18
- 241000238631 Hexapoda Species 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 16
- 241000700618 Vaccinia virus Species 0.000 description 15
- 230000028993 immune response Effects 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 150000007523 nucleic acids Chemical group 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 102100021696 Syncytin-1 Human genes 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 230000002163 immunogen Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 101710091045 Envelope protein Proteins 0.000 description 7
- 102000003886 Glycoproteins Human genes 0.000 description 7
- 108090000288 Glycoproteins Proteins 0.000 description 7
- 101710188315 Protein X Proteins 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 229940126578 oral vaccine Drugs 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 239000012678 infectious agent Substances 0.000 description 6
- 230000001681 protective effect Effects 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 231100000518 lethal Toxicity 0.000 description 5
- 230000001665 lethal effect Effects 0.000 description 5
- 210000000214 mouth Anatomy 0.000 description 5
- 239000002773 nucleotide Chemical group 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000711841 Rabies virus ERA Species 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000007108 local immune response Effects 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000003800 pharynx Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 2
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 2
- 241000282421 Canidae Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101710121417 Envelope glycoprotein Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- YWYQSLOTVIRCFE-SRVKXCTJSA-N Leu-His-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(O)=O)C(O)=O YWYQSLOTVIRCFE-SRVKXCTJSA-N 0.000 description 2
- XZNJZXJZBMBGGS-NHCYSSNCSA-N Leu-Val-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O XZNJZXJZBMBGGS-NHCYSSNCSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241000282579 Pan Species 0.000 description 2
- FHZJRBVMLGOHBX-GUBZILKMSA-N Pro-Pro-Asp Chemical compound OC(=O)C[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1)C(O)=O FHZJRBVMLGOHBX-GUBZILKMSA-N 0.000 description 2
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 108010038633 aspartylglutamate Proteins 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 2
- 229950004398 broxuridine Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 108010032388 glycyl-prolyl-glycyl-arginyl-alanyl-phenylanine Proteins 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 150000002500 ions Chemical group 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229960004184 ketamine hydrochloride Drugs 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- FMKJUUQOYOHLTF-OWOJBTEDSA-N (e)-4-azaniumylbut-2-enoate Chemical compound NC\C=C\C(O)=O FMKJUUQOYOHLTF-OWOJBTEDSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NKDFYOWSKOHCCO-YPVLXUMRSA-N 20-hydroxyecdysone Chemical compound C1[C@@H](O)[C@@H](O)C[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@@](C)(O)[C@H](O)CCC(C)(O)C)CC[C@]33O)C)C3=CC(=O)[C@@H]21 NKDFYOWSKOHCCO-YPVLXUMRSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- ANGAOPNEPIDLPO-XVYDVKMFSA-N Ala-His-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CS)C(=O)O)N ANGAOPNEPIDLPO-XVYDVKMFSA-N 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- FSNVAJOPUDVQAR-AVGNSLFASA-N Arg-Lys-Arg Chemical compound NC(=N)NCCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O FSNVAJOPUDVQAR-AVGNSLFASA-N 0.000 description 1
- ADPACBMPYWJJCE-FXQIFTODSA-N Arg-Ser-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O ADPACBMPYWJJCE-FXQIFTODSA-N 0.000 description 1
- PBVLJOIPOGUQQP-CIUDSAMLSA-N Asp-Ala-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O PBVLJOIPOGUQQP-CIUDSAMLSA-N 0.000 description 1
- FTNVLGCFIJEMQT-CIUDSAMLSA-N Asp-Cys-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CC(=O)O)N FTNVLGCFIJEMQT-CIUDSAMLSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 1
- 241000711506 Canine coronavirus Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- YWEHYKGJWHPGPY-XGEHTFHBSA-N Cys-Thr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N)O YWEHYKGJWHPGPY-XGEHTFHBSA-N 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 241000710829 Dengue virus group Species 0.000 description 1
- 240000006497 Dianthus caryophyllus Species 0.000 description 1
- 235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 208000000655 Distemper Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000725579 Feline coronavirus Species 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000711475 Feline infectious peritonitis virus Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 101150082239 G gene Proteins 0.000 description 1
- DVLZZEPUNFEUBW-AVGNSLFASA-N Glu-His-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@H](CCC(=O)O)N DVLZZEPUNFEUBW-AVGNSLFASA-N 0.000 description 1
- JXYMPBCYRKWJEE-BQBZGAKWSA-N Gly-Arg-Ala Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(O)=O JXYMPBCYRKWJEE-BQBZGAKWSA-N 0.000 description 1
- IHDKKJVBLGXLEL-STQMWFEESA-N Gly-Tyr-Met Chemical compound CSCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)C(O)=O IHDKKJVBLGXLEL-STQMWFEESA-N 0.000 description 1
- 229940033330 HIV vaccine Drugs 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- TWROVBNEHJSXDG-IHRRRGAJSA-N His-Leu-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O TWROVBNEHJSXDG-IHRRRGAJSA-N 0.000 description 1
- 241001207270 Human enterovirus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710843 Japanese encephalitis virus group Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- REPPKAMYTOJTFC-DCAQKATOSA-N Leu-Arg-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O REPPKAMYTOJTFC-DCAQKATOSA-N 0.000 description 1
- FBNPMTNBFFAMMH-AVGNSLFASA-N Leu-Val-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-AVGNSLFASA-N 0.000 description 1
- FBNPMTNBFFAMMH-UHFFFAOYSA-N Leu-Val-Arg Natural products CC(C)CC(N)C(=O)NC(C(C)C)C(=O)NC(C(O)=O)CCCN=C(N)N FBNPMTNBFFAMMH-UHFFFAOYSA-N 0.000 description 1
- SJNZALDHDUYDBU-IHRRRGAJSA-N Lys-Arg-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCCN)C(O)=O SJNZALDHDUYDBU-IHRRRGAJSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 241000712045 Morbillivirus Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 241000609499 Palicourea Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- JEGFCFLCRSJCMA-IHRRRGAJSA-N Phe-Arg-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)O)N JEGFCFLCRSJCMA-IHRRRGAJSA-N 0.000 description 1
- JHSRGEODDALISP-XVSYOHENSA-N Phe-Thr-Asn Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(O)=O JHSRGEODDALISP-XVSYOHENSA-N 0.000 description 1
- MHNBYYFXWDUGBW-RPTUDFQQSA-N Phe-Tyr-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)NC(=O)[C@H](CC2=CC=CC=C2)N)O MHNBYYFXWDUGBW-RPTUDFQQSA-N 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 229940124867 Poliovirus vaccine Drugs 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- MLQVJYMFASXBGZ-IHRRRGAJSA-N Pro-Asn-Tyr Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O MLQVJYMFASXBGZ-IHRRRGAJSA-N 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000711854 Rabies virus PM Species 0.000 description 1
- 101900061860 Rabies virus Phosphoprotein Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000566107 Scolopax Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- HQTKVSCNCDLXSX-BQBZGAKWSA-N Ser-Arg-Gly Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O HQTKVSCNCDLXSX-BQBZGAKWSA-N 0.000 description 1
- 241000589970 Spirochaetales Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 206010041896 St. Louis Encephalitis Diseases 0.000 description 1
- 241000710888 St. Louis encephalitis virus Species 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 1
- CSNBWOJOEOPYIJ-UVOCVTCTSA-N Thr-Thr-Lys Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O CSNBWOJOEOPYIJ-UVOCVTCTSA-N 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- AYPAIRCDLARHLM-KKUMJFAQSA-N Tyr-Asn-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCCCN)C(=O)O)N)O AYPAIRCDLARHLM-KKUMJFAQSA-N 0.000 description 1
- SZTTYWIUCGSURQ-AUTRQRHGSA-N Val-Glu-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O SZTTYWIUCGSURQ-AUTRQRHGSA-N 0.000 description 1
- NLNCNKIVJPEFBC-DLOVCJGASA-N Val-Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O NLNCNKIVJPEFBC-DLOVCJGASA-N 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- 241000120645 Yellow fever virus group Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 108010040443 aspartyl-aspartic acid Proteins 0.000 description 1
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 208000014058 canine distemper Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 description 1
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 108010077515 glycylproline Proteins 0.000 description 1
- 210000004837 gut-associated lymphoid tissue Anatomy 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940099990 ogen Drugs 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 229940023143 protein vaccine Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- 241001147422 tick-borne encephalitis virus group Species 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 244000052613 viral pathogen Species 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 244000000057 wild-type pathogen Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/205—Rhabdoviridae, e.g. rabies virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention relates to compositions for and methods of orally vaccinatir-g mammals using isolated rabies glycoprotein G or chimeric proteins comprising fragments of rabies glycoprotein G and amino ⁇ acid sequences which constitute epitopes against which an immunogenic response may be invoked.
- Oral vaccination is not only economical and easy to administer, it also achieves wide distribution and is therefore particularly suitable for massive immunization.
- a few oral vaccines against viral diseases have been developed and proven to be effective, for example the oral live poliovirus vaccine
- Live attenuated vaccines present risks relating to reversion to virulent forms of the pathogen.
- the use of live recombinant vaccines is associated with concerns and risks associated with the use of infectious agents.
- the present invention relates to oral anti-rabies vaccines that comprise at least 100 ⁇ g of an isolated rabies glycoprotein G that is produced in eukaryotic cells together with a carrier suitable for oral administration.
- the present invention relates to methods of immunizing mammals against rabies infection which comprise the step of orally administering to the mammal, an oral anti-rabies vaccine that comprises at least 100 ⁇ g of an isolated rabies glycoprotein G that is produced in eukaryotic cells.
- the present invention relates to chimeric proteins that are modified rabies glycoprotein G proteins.
- the chimeric proteins comprise native rabies glycoprotein G amino acid sequence except with a 6-30 amino acid sequence substitution between amino acids 20 and 450 of the rabies glycoprotein G amino acid sequence.
- the 6-30 amino acid substitution comprises an amino acid sequence that constitutes a neutralizing epitope from a pathogen antigen.
- the present invention relates to orally active vaccines for immunizing a mammal against a pathogen infection comprising chimeric proteins that are modified rabies glycoprotein G proteins.
- the chimeric proteins comprise native rabies glycoprotein G amino acid sequence except with a 6-30 amino acid sequence substitution between amino acids 20 and 450 of the rabies glycoprotein G amino acid sequence.
- the 6-30 amino acid substitution comprises an amino acid sequence that constitutes a neutralizing epitope from a pathogen antigen.
- the present invention relates to methods of immunizing a mammal against a pathogen infection comprising the step of orally administering to the mammal a chimeric protein.
- the chimeric protein comprises native rabies glycoprotein G amino acid sequence except with a 6-30 amino acid sequence substitution between amino acids 20 and 450 of the rabies glycoprotein G amino acid sequence.
- the 6-30 amino acid substitution comprises an amino acid sequence that constitutes a neutralizing epitope from a pathogen antigen.
- the present invention relates to oral anti-pathogen vaccines that comprise at least 100 ⁇ g of an isolated rabies glycoprotein G that is produced in eukaryotic cells and at least 100 ⁇ g of either an isolated pathogen antigen or a peptide which comprises an amino acid sequence that constitutes a neutralizing epitope of the pathogen.
- the present invention relates to a method of immunizing a mammal against a pathogen infection comprising the step of orally administering to the mammal, an oral anti- pathogen vaccine that comprises at least 100 ⁇ g of an isolated rabies glycoprotein G that is produced in eukaryotic cells and at least 100 ⁇ g of either an isolated pathogen antigen or a peptide which comprises an amino acid sequence that constitutes a neutralizing epitope of the pathogen.
- the present invention provides an orally active anti-rabies vaccine that is an alternative to the recombinant vaccinia approach by providing a non-infectious vaccine which comprises isolated rabies virus G protein.
- the present invention provides oral immunization of mammals, particularly wildlife mammals, especially raccoons without the use of infectious agents.
- the G protein of rabies virus is produced in eukaryotic cells.
- the G protein of rabies virus is produced in insect cells using baculovirus vector.
- the G protein of rabies virus Evelyn Rokitnicki Abelseth (ERA) strain is produced and used in the vaccine.
- the G protein of rabies virus PM strain is produced and used in the vaccine.
- the G protein of rabies virus is produced in insect cells via a baculovirus vector and used for oral vaccination of raccoons against rabies.
- Rabies G protein is provided in a vaccine that is suitable for oral administration isolated from viral particles.
- isolated rabies glycoprotein G is meant to refer to rabies G protein that is not part of an active or inactive virus. It is preferred that a composition comprising the isolated rabies glycoprotein G is essentially free from other rabies viral proteins .
- Rabies G protein may be prepared routinely by recombinant DNA technology using well known techniques.
- the amino acid sequence and nucleotide sequence which encode the G protein are disclosed in Anilionis, A. et al . , (1981) Nature 294:275-278 and Kieny, M.P. et ⁇ l. (1984) Na ture 312 : 163 , each of which is incorporated herein by reference.
- DNA molecules that comprise the coding sequence for rabies G protein can be obtained from natural sources or synthesized or otherwise constructed using widely available starting materials by routine methods.
- Rabies virus DNA is readily available and may alternatively be synthesized by well known techniques using widely available sequence information such as that in the above references .
- G protein To produce G protein, one having ordinary skill in the art can, using well known techniques, obtain a DNA molecule encoding the G protein and insert that DNA molecule into a commercially available expression vector for use in well known expression systems.
- the commercially available plasmid pYES2 Invitrogen, San Diego, CA
- the commercially available MaxBacTM Invitrogen, San Diego, CA
- complete baculovirus expression system may be used for production in insect cells.
- the commercially available plasmid pcDNA I (Invitrogen, San Diego, CA) may be used for production in mammalian cells such as Chinese Hamster Ovary cells.
- Eukaryotic hosts may be transformed with expression systems which produce the desired protein directly, but more commonly signal sequences are provided to effect the secretion of the protein.
- Eukaryotic systems have the additional advantage that they are able to process introns which may occur in the genomic sequences encoding proteins of higher organisms.
- Eukaryotic systems also provide a variety of processing mechanisms which result in, for example, glycosylation, carboxy-terminal amidation, oxidation or derivatization of certain amino acid residues, conformational control, and so forth.
- eukaryotic systems include, but is not limited to, yeast, fungal cells, insect cells, mammalian cells, avian cells, and cells of higher plants.
- Suitable promoters are available which are compatible and operable for use in each of these host types as well as are termination sequences and enhancers, as e.g. the baculovirus polyhedron promoter.
- promoters can be either constitutive or inducible.
- the mouse metallothionene promoter can be induced by the addition of heavy metal ions.
- the particulars for the construction of expression systems suitable for desired hosts are known to those in the art.
- the DNA encoding it is suitably ligated into the expression vector of choice and then used to transform the compatible host which is then cultured and maintained under conditions wherein expression of the foreign gene takes place.
- the protein of the present invention thus produced is recovered from the culture, either by lysing the cells or from the culture medium as appropriate and known to those in the art .
- One having ordinary skill in the art can, using well known techniques, isolate the protein that is produced.
- the G protein may be also isolated from natural sources (Dietzschold et al . 1978 J. Gen . Virol . 40:131-135, which is incorporated herein by reference) .
- the G protein may be administered to an animal orally. At least 100 ⁇ g of protein are administered. A preferred range is at least 100 ⁇ g to 300 ⁇ g. More protein may be administered if available. In some embodiments, a preferred dose is about 300 ⁇ g.
- the protein is preferably encapsulated within wax or another innocuous encasing vehicle and mixed with bait.
- the encased G protein is taken into the oral cavity with the bait .
- the G protein is released and available for intraoral absorption including sublingual absorption. Ingested G protein may be absorbed in the intestine for example.
- the vaccine of the present invention comprises food which is mixed with the isolated G protein.
- the food serves as bait.
- the present invention is particularly useful to immunize raccoons against rabies infection.
- Preferred bait for raccoons includes ground fish.
- 300 ⁇ g of G protein is encapsulated in small wax pellets which are then mixed with ground fish.
- the G protein attaches to cells before entering the stomach. It is believed that, when administered orally, the G protein binds to receptors that are present on cells in the oral cavity or pharynx. It is believed that upon attachment, such cells, which are involved in mucosal immunity, take up the attached protein. Attachment to such cells presents the protein to the immune system before it is degraded by the acids and enzymes in the gastrointestinal tract. The protein is presented as a target for an immune response.
- the discovery that the G protein is useful as an orally active immunogen provides the means to delivery other immunogenic targets by oral administration.
- the G protein or portions thereof may be used as a vehicle or facilitator for the uptake of ether orally administered peptide sequences.
- other immunogenic targets may be linked to G protein and delivered orally as a means to invoke an immune response against the immunogenic target.
- amino acid sequences that constitute neutralizing epitopes of a pathogen antigen may be inserted within the G protein itself to produce a chimeric protein or modified G protein.
- peptides and proteins which comprise amino acid sequences that constitute neutralizing epitopes of a pathogen antigen may be administered together with the G protein as a mixture.
- peptides and proteins which comprise amino acid sequences that constitute neutralizing epitopes of a pathogen antigen may be conjugated to the G protein by either peptide or non-peptide bonds.
- Linkage by peptide bonds produces a fusion protein while linkage by non-peptide bonds produces conjugated compositions including dimers, trimers and other multimers.
- amino acid sequences that constitute neutralizing epitopes of a pathogen antigen and “neutralizing epitope” are used interchangeably and meant to refer to the amino acid sequences which induce a neutralizing immune response against the pathogen from which they are derived.
- amino acid sequences that constitute neutralizing epitopes of a pathogen antigen and can readily identify sequences from a pathogen antigen which induce an immune response against the pathogen which is capable of neutralizing infection by the pathogen.
- One means to screen epitopes for their ability to induce neutralizing immune responses against pathogen infection is to administer a peptide to an animal in order to induce an immune response against the peptide.
- Serum is then withdrawn from the animal and mixed the serum with wild type pathogen.
- the mixture is added to a host of the pathogen such as cells permissive to infection by a viral pathogen. If the host is not infected by the mixture, the presence of neutralizing antibodies in the serum is indicated. Therefore, the peptide has an amino acid sequence that constitute neutralizing epitopes of a pathogen antigen.
- Pathogens for which neutralizing epitopes may be identified from pathogenic antigens are selected from the group consisting of: viruses of the picornavirus family such as rhinoviruses, etheroviruses (including polioviruses, coxsackieviruses, echoviruses, *and human enteroviruses such as hepatitis A virus) and apthoviruses; viruses of the calcivirus family; viruses of the togavirus family; viruses of the flariviridue family such as dengue, yellow fever, Japanese encephalitis, St.
- viruses of the picornavirus family such as rhinoviruses, etheroviruses (including polioviruses, coxsackieviruses, echoviruses, *and human enteroviruses such as hepatitis A virus) and apthoviruses
- viruses of the calcivirus family viruses of the togavirus family
- viruses of the flariviridue family such as dengue, yellow fever,
- hepatitis C virus viruses of the coronavirus family such as feline infectious peritonitis virus, feline enteric coronavirus, canine coronavirus, human respiratory coronaviruses; viruses of the rhabdovirus- Family such as rabies virus; viruses of the filoviridue family such as
- Ebola virus viruses of the paramyxovirus family such as paramyxoviruses (including Mumps virus) , morbillivirus
- viruses of the orthomyxovirus family such as influenza viruses; viruses of the bungavirus family; viruses of the arenavirus family; viruses of the reovirus family such as reoviruses and rotaviruses; viruses of the retrovirus family including oncoriviruses (such as feline leukemia virus, HTLVI and HTLVTI) and lentiviruses (including human immunodeficiency virus and feline immunodeficiency virus) ; viruses of the papovavirus family such as polyomaviruses and papillomavirus; viruses of the adenovirus family; viruses of the parvovirus family; viruses of the herpesvirus family such as HSVI, HSVII, pseudorabies virus, cytomegalovirus and EBV; viruses of the poxvirus family; bacterial pathogens including pathogenic gram-positive cocci, pathogenic gram-negative cocci, pathogenic enteric gram- negative bacilli, pathogenic anaero
- neutralizing epitopes from non-rabies pathogens are inserted into the rabies glycoprotein G in place of rabies glycoprotein G amino acid sequences.
- chimeric proteins are formed which are essentially rabies glycoprotein G but which contain neutralizing epitopes from a pathogen antigen inserted within the rabies glycoprotein G protein in place of native rabies glycoprotein sequences.
- the rabies glycoprotein G sequences provide the necessary sequences to render the chimeric protein orally active.
- the amino acid sequences that constitute neutralizing epitopes of a pathogen antigen present a target for an immune response which will protect the vaccinated individual from infection by the pathogen.
- nucleic acid sequence that encodes G protein can readily engineer by routine molecular biology techniques.
- the amino acid sequence and nucleotide sequence which encode the G protein are disclosed in Anilionis, A. et al . , (1981) Na ture 294:275-278 and Kieny, M.P. et al. (1984) Na ture 312:163, each of which is incorporated herein by reference.
- nucleic acids molecules that encode the G protein as starting material nucleotides sequences that encode the neutralizing epitopes from other pathogens may be inserted into the G protein coding sequence in place of native G protein nucleotide sequences.
- the resulting nucleic acid molecule which encodes a chimeric protein can be used to produce the chimeric protein in well known expression systems such as those which are described above as useful for expressing G protein.
- the chimeric protein may be routinely isolated for preparation and formulation as an orally administered pharmaceutical.
- the isolation, formulation and administration protocols which are described above for isolating, formulating and orally administering the anti-rabies G protein vaccine can be used to in the isolation, formulation and orally administering protocols for anti-pathogen vaccines using the chimeric proteins described herein.
- compositions for and methods of immunizing a mammal against a pathogen infection comprising the step of orally administering to the mammal a chimeric protein which is a modified rabies glycoprotein G.
- the chimeric protein contains insertions of 6- 30 amino acids into rabies G protein.
- the inserted sequences ..omprise an amino acid sequence that constitutes a neutralizing epitope of the pathogen.
- the insertions are made in place of deletions from the rabies glycoprotein G se ⁇ uence between amino acids 20 and 450 of rabies glycoprotein G.
- the insertions are made in place of deletions from the rabies glycoprotein G ERA strain.
- the insertions are made in place of deletions from the rabies glycoprotein G PM strain.
- pharmaceutical compositions are formulated to contain at least 100 ⁇ g of the chimeric protein. In methods of the invention, the pharmaceutical composition which contains at least 100 ⁇ g of the chimeric protein is administered orally. In some embodiments, pharmaceutical compositions are formulated to contain at least 300 ⁇ g of the chimeric protein. In methods of the invention, the pharmaceutical composition which contains at least 300 ⁇ g of the chimeric protein is administered orally. In some preferred embodiments, the mammal to be vaccinated is a human.
- the pathogen to be targeted is selected form the group set out above as the list of pathogens from which neutralizing epitopes of antigens may be identified.
- two or more neutralizing epitopes from the pathogen to be targeted are inserted into the G protein sequence.
- two or more neutralizing epitopes from two or more pathogens, respectively, to be targeted are inserted into the G protein sequence.
- the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 6-25 amino acids. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 8-20 amino acids.
- the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 9-15 amino acids. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 9 amino acids. In some embodiments, the neutralizing epitope is a 6-9 amino acid sequence which is within a 9 ar.ino acid sequence inserted into rabies glycoprotein G at positions 191-198 in place of the rabies G protein sequences. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 20-25 amino acids. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 23 amino acids. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 20- 23 amino acids which is inserted within a 23 amino acid sequences inserted into rabies glycoprotein G at positions 253- 275.
- the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 175 and 225 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 185 and 215 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 190 and 205 of the rabies glycoprotein G.
- the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 191 and 198 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 240 and 295 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 245 and 290 of the rabies glycoprotein G.
- the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 250 and 280 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 253 and 275 of the rabies glycoprotein G.
- the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 8-25 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 175 and 225 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 9-15 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 185 and 215 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 9-15 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 190 and 205 of the rabies glycoprotein G.
- the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 9 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 191 and 198 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 20-25 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 240 and 295 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 20-25 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 245 and 290 of the rabies glycoprotein G.
- the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 20-25 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 250 and 280 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 23 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 253 and 275 of the rabies glycoprotein G.
- chimeric proteins may be modified rabies glycoprotein G in which amino acid sequences which define neutralizing epitopes for non-rabies pathogens are inserted in place of G protein sequences. These substitutions are preferably amino acid for amino acid, that is a six amino acid sequence which constitutes a non-rabies neutralizing epitope is inserted into rabies G protein in place of six deleted sequences from rabies G protein. It is contemplated that inserts which contain additional amino acids may be inserted into deletion sites and that inserts which contain fewer amino acids may be inserted into deletion sites. It is also contemplated that portions of the G protein will be deleted without a corresponding insert form a non-rabies pathogen antigen.
- truncated forms of the G protein are linked to amino acid sequences that constitutes a neutralizing epitope of the pathogen.
- Such fusion proteins contain the portion of the G protein which attaches to the receptor and renders the molecule orally active and an epitope against which an immune response can be directed to protect against non-rabies infection.
- the term "orally active fragment of G protein” refers to a fragment of the G protein which retains the unexpected ability to be taken up and invoke an immune response when orally administered. When administered orally, orally active fragments of the G protein are able to be presented as immunogenic targets against which an immune response is induced.
- neutralizing epitopes form non-rabies pathogens are linked to orally active fragments of G protein.
- the portion of the chimeric protein which is an orally active fragment of G protein attaches to cells in the oral cavity and pharynx.
- An immune response is invoked against the non-rabie: neutralizing epitope of the chimeric protein.
- compositions fcr and methods ofr immunizing a mammal against a pathogen infection are provided. The compositions orally administered to the mammal .
- compositions comprise at least 100 ⁇ g of isolated rabies glycoprotein G produced in eukaryotic cells and at least 100 ⁇ g of a pathogen protein which comprises a neutralizing epitope.
- the rabies glycoprotein G and the peptide or protein which comprises the neutralizing epitope of a non-rabies pathogen are unlinked and in some embodiments, the rabies glycoprotein G and the peptide or protein which comprises the neutralizing epitope of a non- rabies pathogen are linked by peptide or non-peptide bonds.
- the rabies glycoprotein G When orally administered, the rabies glycoprotein G are taken up by the cells of the oral cavity and pharynx and the peptide or protein which comprises the neutralizing epitope of a non- rabies pathogen, whether linked or unlinked to the rabies G protein is similarly taken up.
- the amino acid sequences that constitute neutralizing epitopes of a pathogen antigen present a target for an immune response which will protect the vaccinated individual from infection by the pathogen.
- the rabies glycoprotein G is described above.
- the rabies glycoprotein G is from rabies ERA strain.
- Those having ordinary skill in the art can readily produce peptides and proteins which comprise an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen.
- Such amino acid sequences which induce an immune response against the pathogen which is capable of neutralizing infection by the pathogen, can be readily identified from a pathogen antigen.
- the composition comprises a non-rabies pathogen antigen.
- compositions are formulated to contain at least 100 ⁇ g of the rabies G protein and at least 100 ⁇ g of the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen.
- the pharmaceutical composition which contains at least 100 ⁇ g of the rabies G protein and 100 ⁇ g of peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pat_ ogen antigen is administered orally.
- compositions are formulated to contain at least 300 ⁇ g of the rabies G protein and at least 100 ⁇ g of the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen.
- the pharmaceutical composition which contains at least 300 ⁇ g of the rabies G protein and 100 ⁇ g of peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is administered orally.
- compositions are formulated to contain at least 100 ⁇ g of the rabies G protein and at least 300 ⁇ g of the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen.
- the pharmaceutical composition which contains at least 100 ⁇ g of the rabies G protein and 300 ⁇ g of peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is administered orally.
- pharmaceutical compositions are formulated to contain at least 300 ⁇ g of the rabies G protein and at least 300 ⁇ g of the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen.
- the pharmaceutical composition which contains at least 300 ⁇ g of the rabies G protein and 300 ⁇ g of peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is administered orally.
- compositions and methods of the present invention can be applied to human medical and veterinary medical uses.
- the present invention relates to compositions and methods of immunizing mammals, particularly humans and bovine, ovine, porcine, equine, canine and feline species.
- the mammal to be vaccinated is a human.
- the pathogen to be targeted is selected from the group consisting of those pathogens set out above.
- the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is linked to the rabies glycoprotein G.
- the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is linked to the rabies glycoprotein G by peptide bonds.
- the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is linked to the rabies glycoprotein G by non-peptide bonds.
- the peptide and protein which comprises an amino ⁇ d sequences that constitutes neutralizing epitopes of a pathogen antigen i ⁇ _nked to the rabies glycoprotein G by disulfide bonds In some embodiments, at least 2, and in some preferred embodiments, multiple copies of the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is linked to each rabies glycoprotein G molecule.
- compositions of the present invention are useful as components together with other vaccine compositions to form multivalent vaccines.
- Other components include other orally active vaccine products polio vaccines. Examples Example 1
- the G protein gene of rabies virus ERA strain was recovered from plasmid ptgl55pro8 (Kieny, M.P..,et al . (1984) Na ture 312:163) by digestion with Bgrlll restriction enzyme (Boehringer Mannheim Biochemicals) and subsequently cloned into the unique BamHI site of baculovirus transfer vector pVL941 (Luckow,V.A. and Summers, M.D. (1898) Virology 170:31 which is incorporated herein by reference) .
- a recombinant plasmid with the G gene in the correct orientation in relation to the polyhedron promoter was obtained and cotransfected with
- Au tographa calif ornica nuclear polyhidrosis virus (Ac ⁇ PV) D ⁇ A into Spodoptera Frugiperda (Sf9) cells.
- BVRG was selected by limited dilution in combination with dot-blot hybridization and plaque purification, as described (Summers, M.D. and Smith, G.E. 1987 Tex. Agric . Exp . St . Bull . 1555:1 which is incorporated herein by reference) .
- Sf9 cells grown in a 24-well plate were mock-infected or infected with Ac ⁇ PV or the recombinant baculoviruses BVLRG at multiplicity of infection of 10 plaque forming units per cell.
- the culture medium was removed and 200 ⁇ l methionine-free Grace's medium was added to each well. After incubation for 1 h, the medium was replaced with fresh methionine-free Grace's medium mixed with 30 ⁇ Ci
- the G protein expressed in Sf9 cells migrated slightly faster on the gels compared to the native G protein of ERA strain of rabies virus. It can also be seen from the pattern of the wild-type AcNPV that there is a protein of the wild-type virus that comigrates with the G protein expressed in Sf9 cells. After the proteins on the gel were transferred to nitrocellulose paper, only the G protein from BVLRG-infected cells and the G protein of rabies virus reacted with rabbit anti-G polyclonal antibodies. Although the G protein expressed in insect cells reacted with the rabbit anti-G polyclonal antisera in the Western blot assay, it was uncertain whether or not the G protein expressed in cells retained its native structure.
- Sf9 cells as -n oral vaccine in raccoons against lethal rabies virus infection
- Sf9 cells were infected with BVLRG, harvested at 60 h po ⁇ tinfection and lysed with either 1% Triton X-100 or 1% ( ⁇ -octylpyranoglucoside. The lysates were then centrifuged at 10 000 g for 20 min and the supernatants were recovered. The concentration of G protein in the supernatant was estimated by SDS-polyacrylamide gel electrophoresis using known amounts of purified rabies virion G protein as standard markers (data not shown) .
- Serum neutralization antibody titers against rabies were determined using a modification of the rapid fluorescent focus-inhibition test, as described by Wiktor et al . 1983 Dev. Biol . Stand . 57:199. Vaccinated animals, as well as controls, were challenged with a street rabies virus and observed for three months after challenge for disease and deaths. Six of the seven immunized raccoons survived the challenge while all of the controls succumbed to rabies and dies within 30 days of challenge (Table 2) .
- the protective effect of oral administration of rabies glycoprotein G isolated from virus particles was determined as follows.
- the Fix Rabies Virus ERA (The Wistar Institute virus collection, Philadelphia, PA) was propagated on BHK-21 cell monolayers grown at 37°C minimum essential medium supplemented with 10% fetal calf serum. Cell cull supernatants were harvested and inactivated by beta propylactone (BPL) treatment
- the virus suspension was then concentrated and purified by zonal ultracentrifugation on a sucrose gradient. Each purified virus was suspended in phosphate-buffered saline and was adjusted to a protein concentration of 10 micrograms per microliter. Inactivated virus was purified by adding an equal volume of 4% OGP-NT buffer and incubated for one hour at room temperature. The suspension was centrifuged on a 25% sucrose cushion (NaCl 0.5 M, OGP 2%) in an SW 50 rotor at 12,000 G for 100 minutes at 4°C. The despiculated viral particles were in the sediment. The supernatant was harvested and adjusted to 2.5% sucrose by adding NT buffer.
- a sucrose gradient was prepared in NaCl 0.5 M, OGP 2% with three layers: one ml at 60% (W/V) , 8 ml of linear gradient 5 to 25% . (W/V) ; and one ml at 3% (W/V) .
- the glycoprotein suspension was deposited onto the sucrose gradient and centrifuged in a SW 41 rotor at 150,000 G for 36 hours at 4° centigrade. Fractions were harvested in quantities of 0.5 ml from the bottom of the tubes. Fractions which contain glycoproteins are identified. The glycoprotein solution is dialyzed against NT buffer overnight_at 4°C and sterilized by filtration through a .22 ⁇ membrane.
- rabies seronegative adult raccoons 1-5 years of age. Prior to handling, all animals were sedated by intramuscular administration of .5 to 1.0 ml of ketamine hydrochloride. Raccoons were given rabies viral G protein per os by needleless syringe: One group of raccoons consisting of six animals was sedated and administered a single 1.0 ml dose of 100 micrograms of ERA rabies G vaccine per os . A second group of raccoons received 1.0 ml of PBS by installation directly into the mouth as a control .
- HIVs human immunodeficiency viruses
- AIDS acquired immunodeficiency syndrome
- the envelope glycoprotein gpl20 (or gpl60) has been the major target for developing candidate vaccines against AIDS since gpl20 recognizes the cellular receptor (CD4) on T lymphocytes and induces neutralizing antibodies.
- a principal neutralization determinant (PND) has been identified and is located in the third variable domain of the gpl20.
- Chimeric genes containing rabies G protein sequences and PND sequences of HIV-1 gpl20 are constructed by replacing linear and/or discontinuous epitopes of rabies virus G protein with PND sequences of HIV-1 gpl20. In some embodiments these chimeric proteins are expressed in mammalian cells via vaccinia virus vectors and in insect cells via baculovirus vectors .
- gpl20 and the transmembrane protein of 41 kDa (gp41) , both of which are derived from a common precursor, gpl60. It was shown that recombinant proteins or viruses, like the native proteins purified from HIV-infected cells, induced high levels of HIV- specific antibodies, some with neutralizing activity, in experimental animals or human volunteers. Immunization of monkeys with the recombinant proteins purified from CHO cells have resulted in the induction of neutralizing antibodies and some of the immunized monkeys with high neutralizing antibody titers were protected against a challenge infection with homologous virus strain.
- GPGRAF SEQ ID NO: 1
- SEQ ID NO: 1 sequence in the central portion of V3 loop, GPGRAF (SEQ ID NO: 1) .
- sequence in the central portion of V3 loop is relatively conserved although the sequences flanking the GPGRAF (SEQ ID NO: 1) regions in these isolates may be different.
- Over 65% of HIV-1 positive sera reacted with peptides containing this sequence.
- Monoclonal antibodies selected against the PND have been shown to neutralize Hi infectivity in vi tro and to protect chimpanzees against HIV challenge infection in vivo .
- subunit vaccines such as the envelope proteins (gpl20 and gpl ⁇ O) or peptides derived from it can stimulate the production of neutralizing antibodies in immunized animals or humans.
- the results obtained from immunized monkeys also show that vaccination with these subunit vaccines can also protect against infection if the neutralizing antibcdy titers are high enough at the time of challenge.
- the peptide vaccines derived from PND may have some advantages over the entire envelope protein since some antibodies to the envelope protein but not to the PND have been shown to enhance HIV infectivity in vi tro although this has not been reported in vivc
- rabies virus glycoprotein ' is used as a vehicle to target HIV antigens to the pregastric mucous membrane since rabies virus G protein is a superb oral immunogen and can induce systemic immune responses when given orally.
- a linear neutralizing epitope has been defined on the G protein and immunization with a peptide derived from this epitope resulted in the production of neutralizing antibodies and protected mice against lethal challenge, which provide the sites to engineer HIV epitopes.
- the chimeric protein will be expressed either in insect cells via baculovirus or in mammalian cells by vaccinia viruses and then studied for its antigenicity and immunogenicity.
- rabies virus glycoprotein is a good oral immunogen
- rabies virus glycoprotein is a good oral immunogen
- the G protein gene of rabies virus ERA strain was recovered from plasmid ptg 155pro8 by digestion with Bglll restriction enzyme and cloned into the unique BamHI site of a baculovirus transfer vector pVL941. After cotransfection of the recombinant plasmid and wide type baculovirus DNA into Sf9 cells, the recombinant baculovirus containing the rabies virus G protein was selected.
- rabies virus G protein is a good oral immunogen and can induce neutralizing antibodies and protect immunized animals against lethal challenge when given orally.
- SEQ ID NO: 4 is the 5' end of rabies G protein with the incorporation of a Bglll site and oligonucleotide number 4 is near the 3' end of rabies G protein with the incorporation of a Clal site.
- SEQ ID NOS: 5 and 6 represent the site for mutation, each has 15 nucleotides for basepairing and 27 nucleotides (coding the changed 9 amino acids) overhang.
- PCR was performed with SEQ ID NOS: 4 and 5 or SEQ ID NOS: 6 and 7 using ptgl55pro8 as template.
- a Fragment with 0.7 kb was obtained with SEQ ID NOS: 6 and 7 and another fragment with 1.0 kb was obtained with SEQ ID NOS: 6 and 7.
- Oligo 1 ACTGGCAAGATCTAATATGGTTCCTCAG (SEQ ID NO:4)
- Oligo 2 AAACGCTCTCCCAGGCCCAATGTGAATGTCACAAGACATCCC (SEQ ID NO:
- Oligo 3 ATTCACATTGGGCCTGGGAGAGCGTTTGCATCCAAAGGGAGT (SEQ ID NO: 1
- Oligo 4 GCGTAGGTTCTGATCGATTGACTCTTC (SEQ ID NO:7)
- HIV antigens are targeted to the pregastric mucous membrane using rabies virus G protein as a delivering vehicle.
- the chimeric genes are constructed and expressed (rabies G-HIV PND) in vaccinia virus or baculoviruses. Construction of chimeric gene at the discontinuous epitope site is performed as follows. As described above, the chimeric gene amplified by overlapping PCR is digested with Bglll and Clal and cloned into ptgl55pro8 also digested with the same enzymes. Alter ligation and transformation, the chimeric gene is sequenced using the primer extension method to make sure that the amplified gene has the correct HIV PND se ⁇ uence in frame.
- the chimeric gene in the resulting clone has the complete coding sequence for rabies virus G protein within two Bglll sites as the original ptgl55pro8. Construction of chimeric genes at the linear epitope site is performed as follows. A linear epitope was mapped to residue 253 to 275 (23 residues) of the rabies virus G protein by MAb 6-15C4, which provides a site for replacement with sequence derived from HIV PND. This epitope is located between two restriction enzyme sites on the rabies virus G protein gene, with BanI at the 5' end and Aatll at the 3' end. Two chimeric genes are constructed at this site. First, this epitope on rabies G protein (23 amino acids) is replaced by exact 23 amino acids derived from the PND of HIV MN strain.
- MN strain YNKRKRIHIGPGRAFYTTKNIIG (SEQ ID NO: 9) .
- two synthetic oligonucleotides (SEQ ID NO: 10 and SEQ ID NO:ll) with restriction sites at each end, BanI at the 5' end and Aatll at the 3' end are use These oligonucleotides will be annealed and phosphorylated, which is then cloned into ptgl55pro8 digested with BanI and Aatll.
- the chimeric genes are transformed and clones with the correct mutagenesis are selected for -cloning into baculovirus or vaccinia virus transfer vectors.
- Expression o£ chimeric genes by vaccinia virus vectors is accomplished as follows. To express these chimeric genes in vaccinia virus, the protocol used to express rabies virus G protein in vaccinia virus are followed. The chimeric genes described above are digested with Bglll and cloned into the unique BamHI site of ptglH-Tk-P7.5.
- the resulting clones are screened and sequenced to select those clones with the chimeric genes in the correct orientation, which are then co-transfected with wild type vaccinia virus (Copenhagen strain) into HeLa fibroblasts. HeLa cells are infected with wide type vaccinia virus two hours before recombinant plasmids are transfected.
- wild type vaccinia virus Copenhagen strain
- Recombinant vaccinia virus expressing these chimeric proteins are selected by infecting TK " 143 osteosarcoma cells in the presence of 5-bromodeoxyuridine (BrdUrd) .
- virus eluted from plaques selected in TH " cells are used to infect HeLa cells in 6-well plates at the multiplicity of infection (moi) of 10 plaque forming units (pfu) per cell.
- m multiplicity of infection
- pfu plaque forming units
- the chimeric genes are expressed in insect cells via baculovirus vectors as follows. To express these chimeric proteins in insect-cells via baculovirus vectors, the chimeric genes are digested with Bglll and cloned into the unique BamHI site of pVL941. The resulting clones are screened and sequenced to select one clone with the chimeric gene in the correct orientation in relation to the polyhedron promoter, which will then be co-transfected with AcNPV DNA into Sf9 cells. The method of limited dilution, combined with DNA dot- blot hybridization is used to detect and select recombinant baculovirus containing these chimeric genes.
- the recombinant baculoviruses are purified by plaque purification and used for the production of recombinant baculovirus stocks.
- the recombinant baculoviruses containing these chimeric genes are used to infect Sf9 cells in a 6-well plate at moi of approximately 10 pfu per cell. Infected cells are harvested at 60 hours post infection, lysed with protein disruption buffer and subjected to electrophoresis on a 10% polyacrylamide gel containing SDS. Proteins separated on the gel are electrotransferred to nitrocellulose paper and reacted with antibodies to rabies virus G protein, antibodies to V3 loop of MN strain, or sera from HIV-positive patients. Immunofluorescent antibody assays are also used to make sure that the chimeric G proteins expressed in insect cells retain its native structure. Rabies virus G protein expressed in insect cells and gpl60 of HIV are included as positive controls . TABLE I
- GTGCTATAAC AAACGCAAGC GGATTCACAT CGGGCCTGGG AGAGCCTTCT ATACGACCAA 60
- GTGCTGTACC AGGCCTAACT ATAACAAGAG AAAGAGAATT CACATTGGGC CTGGGAGAGC 60
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Oral anti-rabbies vaccines that comprise at least 100 νg of an isolated rabies glycoprotein G that is produced in eukaryotic cells and methods of immunizing mammals against rabies infection which comprise the step of orally administering to the mammal, such oral anti-rabies vaccine are disclosed. Chimeric proteins are disclosed. Orally active vaccines for immunizing a mammal against a pathogen infection comprising chimeric proteins and methods of using the same are disclosed. Oral anti-pathogen vaccines that comprise at least 100 νg of an isolated rabies glycoprotein G and either an isolated pathogen antigen or a peptide which comprises a neutralizing epitope of a pathogen antigen and methods of using the same are disclosed.
Description
Oral Vaccination of Mammals
Field of the Invention
The present invention relates to compositions for and methods of orally vaccinatir-g mammals using isolated rabies glycoprotein G or chimeric proteins comprising fragments of rabies glycoprotein G and amino^acid sequences which constitute epitopes against which an immunogenic response may be invoked.
Background of the Invention
Oral vaccination is not only economical and easy to administer, it also achieves wide distribution and is therefore particularly suitable for massive immunization. A few oral vaccines against viral diseases have been developed and proven to be effective, for example the oral live poliovirus vaccine
(Sabin, A.B. and Boulger, L.R. (1973) J. Biol . Stand. 1:115) . However, all oral vaccines currently in use or under clinical trail are either live-attenuated or live-recombinant viruses
(Ada, G. . (1990) Semin . Vircl . 1:3; Blancou, J. , et al. (1986)
Nature 322:373; Rupprecht, C.E., et al . (1986) Proc . Natl Acad.
Sci USA 83:7949) . Live attenuated vaccines present risks relating to reversion to virulent forms of the pathogen. The use of live recombinant vaccines is associated with concerns and risks associated with the use of infectious agents.
Wildlife rabies exists in may countries and continues to present a major public health threat. Efforts to control wildlife rabies during the past decade in both Europe and North America have been directed toward oral vaccination of free-
ranging wildlife with live-attenuated rabies virus in bait
(Wandeler, A.I. In: The Na tural History of Rabies , 2nd ed.
(Ed. Baer, G. .) . CRC Press, Boca Raton, Florida, p. 485-503, which is incorporated herein by reference) . It has been proven to be very successful, especially in foxes (Baer, G.M. (1988)
.Rev. Infect . Dis . 10, S644; Schneider, L.G., et al . (1988) Rev.
Infect . Dis . 10 S654) . In the past few years, raccoon rabies has spread from the southeastern to the mid-atlantic region of the USA. Recently, a vaccinia recombinant virus containing the rabies glycoprotein (G) (Kieny, M.P..,et al.. (.1984) Na ture 312:163) has been developed and demonstrated to be effective against rabies virus infection under laboratory conditions (Blancou, J., et al . (1986) Na ture 322 :373 ; Rupprecht, C.E., et al . (1986) Proc . Na tl Acad. Sci USA 83:7949; Wiktor, T.J., et al . (1984) Proc . Na tl Acad. Sci . USA 81: 7194) . Field trials with this recombinant vaccine in foxes has resulted in large- scale elimination of rabies in vaccinated areas in Europe. Field trials with the same vaccine are currently underway in raccoons in the United States. Laboratory experiments have been reported which described effective vaccination of raccoons by oral administration of inactivated rabies virus P strain (Rupprecht, C.E., et al. (1992) J. Wildlife Diseases 28 (4) : 629- 635) .
The use of live-attenuated virus as a means of vaccinating animals requires that live infectious agents be placed in the environment. Such vaccination methods are accompanied by risks. There is a need for an oral vaccine against rabies infection which does not require the use of infectious agents. Oral vaccines are additionally desirable as an alternative to injectable vaccines. For human vaccines, oral vaccines offer alternatives to other modes of administration which are associated with discomfort. Furthermore, there is a desire to eliminate the use of needle syringes whenever possible to reduce the transmission of any infectious agents between the vaccinated individual and the vaccine administrator. With respect to veterinary vaccines, the ease
of delivering vaccines in high volume using oral administration presents advantages over other modes of administering vaccines. There remains a need to provide effective oral vaccines against rabies without the use of infectious agents or carriers . There remains a need to develop methods and compositions for oral vaccination against pathogens.
Summary of the Invention
The present invention relates to oral anti-rabies vaccines that comprise at least 100 μg of an isolated rabies glycoprotein G that is produced in eukaryotic cells together with a carrier suitable for oral administration.
The present invention relates to methods of immunizing mammals against rabies infection which comprise the step of orally administering to the mammal, an oral anti-rabies vaccine that comprises at least 100 μg of an isolated rabies glycoprotein G that is produced in eukaryotic cells.
The present invention relates to chimeric proteins that are modified rabies glycoprotein G proteins. The chimeric proteins comprise native rabies glycoprotein G amino acid sequence except with a 6-30 amino acid sequence substitution between amino acids 20 and 450 of the rabies glycoprotein G amino acid sequence. The 6-30 amino acid substitution comprises an amino acid sequence that constitutes a neutralizing epitope from a pathogen antigen. The present invention relates to orally active vaccines for immunizing a mammal against a pathogen infection comprising chimeric proteins that are modified rabies glycoprotein G proteins. The chimeric proteins comprise native rabies glycoprotein G amino acid sequence except with a 6-30 amino acid sequence substitution between amino acids 20 and 450 of the rabies glycoprotein G amino acid sequence. The 6-30 amino acid substitution comprises an amino acid sequence that constitutes a neutralizing epitope from a pathogen antigen.
The present invention relates to methods of immunizing a mammal against a pathogen infection comprising the step of orally administering to the mammal a chimeric protein. The
chimeric protein comprises native rabies glycoprotein G amino acid sequence except with a 6-30 amino acid sequence substitution between amino acids 20 and 450 of the rabies glycoprotein G amino acid sequence. The 6-30 amino acid substitution comprises an amino acid sequence that constitutes a neutralizing epitope from a pathogen antigen.
The present invention relates to oral anti-pathogen vaccines that comprise at least 100 μg of an isolated rabies glycoprotein G that is produced in eukaryotic cells and at least 100 μg of either an isolated pathogen antigen or a peptide which comprises an amino acid sequence that constitutes a neutralizing epitope of the pathogen.
The present invention relates to a method of immunizing a mammal against a pathogen infection comprising the step of orally administering to the mammal, an oral anti- pathogen vaccine that comprises at least 100 μg of an isolated rabies glycoprotein G that is produced in eukaryotic cells and at least 100 μg of either an isolated pathogen antigen or a peptide which comprises an amino acid sequence that constitutes a neutralizing epitope of the pathogen.
Detailed Description of the Invention
According to some embodiments, the present invention provides an orally active anti-rabies vaccine that is an alternative to the recombinant vaccinia approach by providing a non-infectious vaccine which comprises isolated rabies virus G protein. The present invention provides oral immunization of mammals, particularly wildlife mammals, especially raccoons without the use of infectious agents. In some embodiments, the G protein of rabies virus is produced in eukaryotic cells. In some embodiments, the G protein of rabies virus is produced in insect cells using baculovirus vector. In some embodiments, the G protein of rabies virus Evelyn Rokitnicki Abelseth (ERA) strain is produced and used in the vaccine. In some embodiments, the G protein of rabies virus PM strain is produced and used in the vaccine. In some embodiments the G protein of rabies virus is produced in insect cells via a
baculovirus vector and used for oral vaccination of raccoons against rabies.
As used herein, the terms '-'rabies G protein" and rabies glycoprotein G" are used interchangeably. Rabies G protein is provided in a vaccine that is suitable for oral administration isolated from viral particles. As used herein, the terms "isolated rabies glycoprotein G" is meant to refer to rabies G protein that is not part of an active or inactive virus. It is preferred that a composition comprising the isolated rabies glycoprotein G is essentially free from other rabies viral proteins .
Rabies G protein may be prepared routinely by recombinant DNA technology using well known techniques. The amino acid sequence and nucleotide sequence which encode the G protein are disclosed in Anilionis, A. et al . , (1981) Nature 294:275-278 and Kieny, M.P. et βl. (1984) Na ture 312 : 163 , each of which is incorporated herein by reference. DNA molecules that comprise the coding sequence for rabies G protein can be obtained from natural sources or synthesized or otherwise constructed using widely available starting materials by routine methods. Rabies virus DNA is readily available and may alternatively be synthesized by well known techniques using widely available sequence information such as that in the above references . When the DNA that encodes the G protein is prepared synthetically, advantage can be taken of known codon preferences of the intended host where the DNA is to be expressed.
To produce G protein, one having ordinary skill in the art can, using well known techniques, obtain a DNA molecule encoding the G protein and insert that DNA molecule into a commercially available expression vector for use in well known expression systems. For example, the commercially available plasmid pYES2 (Invitrogen, San Diego, CA) may be used for production in S . cerevisiae strains of yeast. The commercially available MaxBac™ (Invitrogen, San Diego, CA) complete baculovirus expression system may be used for production in insect cells. The commercially available plasmid pcDNA I
(Invitrogen, San Diego, CA) may be used for production in mammalian cells such as Chinese Hamster Ovary cells.
One having ordinary skill in the art may use these or other commercially available expression vectors and systems or produce vectors using well known methods and readily available starting materials. Expression systems containing the requisite control sequences, such as promoters and polyadenyla ion signals, and preferably enhancers, are readily available and known in the art for a variety of hosts. See e . g. , Sambrook et al . , Molecular Cloning a Labora tory Manual , Second Ed. Cold Spring Harbor Press (1989) . Thus, the desired proteins can be prepared in both prokaryotic and eukaryotic systems, resulting in a spectrum of processed forms of the protein. A wide variety of eukaryotic hosts are available for production of recombinant foreign proteins. Eukaryotic hosts may be transformed with expression systems which produce the desired protein directly, but more commonly signal sequences are provided to effect the secretion of the protein. Eukaryotic systems have the additional advantage that they are able to process introns which may occur in the genomic sequences encoding proteins of higher organisms. Eukaryotic systems also provide a variety of processing mechanisms which result in, for example, glycosylation, carboxy-terminal amidation, oxidation or derivatization of certain amino acid residues, conformational control, and so forth.
Commonly used eukaryotic systems include, but is not limited to, yeast, fungal cells, insect cells, mammalian cells, avian cells, and cells of higher plants. Suitable promoters are available which are compatible and operable for use in each of these host types as well as are termination sequences and enhancers, as e.g. the baculovirus polyhedron promoter. As above, promoters can be either constitutive or inducible. For example, in mammalian systems, the mouse metallothionene promoter can be induced by the addition of heavy metal ions. The particulars for the construction of expression systems suitable for desired hosts are known to those in the
art. For recombinant production of the protein, the DNA encoding it is suitably ligated into the expression vector of choice and then used to transform the compatible host which is then cultured and maintained under conditions wherein expression of the foreign gene takes place. The protein of the present invention thus produced is recovered from the culture, either by lysing the cells or from the culture medium as appropriate and known to those in the art .
One having ordinary skill in the art can, using well known techniques, isolate the protein that is produced.
The G protein may be also isolated from natural sources (Dietzschold et al . 1978 J. Gen . Virol . 40:131-135, which is incorporated herein by reference) .
The G protein may be administered to an animal orally. At least 100 μg of protein are administered. A preferred range is at least 100 μg to 300 μg. More protein may be administered if available. In some embodiments, a preferred dose is about 300 μg.
In administering the vaccine of the present invention to animals in the wild, the protein is preferably encapsulated within wax or another innocuous encasing vehicle and mixed with bait. When the wild animal consumed the bait, the encased G protein is taken into the oral cavity with the bait . When chewed, the G protein is released and available for intraoral absorption including sublingual absorption. Ingested G protein may be absorbed in the intestine for example.
For administration to wildlife, the vaccine of the present invention comprises food which is mixed with the isolated G protein. The food serves as bait. The present invention is particularly useful to immunize raccoons against rabies infection. Preferred bait for raccoons includes ground fish. In some embodiments, 300 μg of G protein is encapsulated in small wax pellets which are then mixed with ground fish.
It is believed that, when administered orally, the G protein attaches to cells before entering the stomach. It is believed that, when administered orally, the G protein binds to receptors that are present on cells in the oral cavity or
pharynx. It is believed that upon attachment, such cells, which are involved in mucosal immunity, take up the attached protein. Attachment to such cells presents the protein to the immune system before it is degraded by the acids and enzymes in the gastrointestinal tract. The protein is presented as a target for an immune response.
The discovery that the G protein is useful as an orally active immunogen provides the means to delivery other immunogenic targets by oral administration. The G protein or portions thereof may be used as a vehicle or facilitator for the uptake of ether orally administered peptide sequences. In particular, other immunogenic targets may be linked to G protein and delivered orally as a means to invoke an immune response against the immunogenic target. Thus, amino acid sequences that constitute neutralizing epitopes of a pathogen antigen may be inserted within the G protein itself to produce a chimeric protein or modified G protein. Alternatively, peptides and proteins which comprise amino acid sequences that constitute neutralizing epitopes of a pathogen antigen may be administered together with the G protein as a mixture. It is also within the scope of the invention that peptides and proteins which comprise amino acid sequences that constitute neutralizing epitopes of a pathogen antigen may be conjugated to the G protein by either peptide or non-peptide bonds. Linkage by peptide bonds produces a fusion protein while linkage by non-peptide bonds produces conjugated compositions including dimers, trimers and other multimers.
As used herein, the terms "amino acid sequences that constitute neutralizing epitopes of a pathogen antigen" and "neutralizing epitope" are used interchangeably and meant to refer to the amino acid sequences which induce a neutralizing immune response against the pathogen from which they are derived. Those having ordinary skill in the art can readily appreciate what is meant by "amino acid sequences that constitute neutralizing epitopes of a pathogen antigen" and can readily identify sequences from a pathogen antigen which induce an immune response against the pathogen which is capable of
neutralizing infection by the pathogen. One means to screen epitopes for their ability to induce neutralizing immune responses against pathogen infection is to administer a peptide to an animal in order to induce an immune response against the peptide. Serum is then withdrawn from the animal and mixed the serum with wild type pathogen. The mixture is added to a host of the pathogen such as cells permissive to infection by a viral pathogen. If the host is not infected by the mixture, the presence of neutralizing antibodies in the serum is indicated. Therefore, the peptide has an amino acid sequence that constitute neutralizing epitopes of a pathogen antigen.
Pathogens for which neutralizing epitopes may be identified from pathogenic antigens are selected from the group consisting of: viruses of the picornavirus family such as rhinoviruses, etheroviruses (including polioviruses, coxsackieviruses, echoviruses, *and human enteroviruses such as hepatitis A virus) and apthoviruses; viruses of the calcivirus family; viruses of the togavirus family; viruses of the flariviridue family such as dengue, yellow fever, Japanese encephalitis, St. Louis encephalitis and tick borne encephalitis viruses; hepatitis C virus; viruses of the coronavirus family such as feline infectious peritonitis virus, feline enteric coronavirus, canine coronavirus, human respiratory coronaviruses; viruses of the rhabdovirus- Family such as rabies virus; viruses of the filoviridue family such as
Ebola virus; viruses of the paramyxovirus family such as paramyxoviruses (including Mumps virus) , morbillivirus
(including measles, canine distemper) and pneu invirus
(including respiratory syncytial virus) ; viruses of the orthomyxovirus family such as influenza viruses; viruses of the bungavirus family; viruses of the arenavirus family; viruses of the reovirus family such as reoviruses and rotaviruses; viruses of the retrovirus family including oncoriviruses (such as feline leukemia virus, HTLVI and HTLVTI) and lentiviruses (including human immunodeficiency virus and feline immunodeficiency virus) ; viruses of the papovavirus family such as polyomaviruses and papillomavirus; viruses of the adenovirus
family; viruses of the parvovirus family; viruses of the herpesvirus family such as HSVI, HSVII, pseudorabies virus, cytomegalovirus and EBV; viruses of the poxvirus family; bacterial pathogens including pathogenic gram-positive cocci, pathogenic gram-negative cocci, pathogenic enteric gram- negative bacilli, pathogenic anaerobic bacteria, and pathogenic spirochetes, and pathogenic protozoans such as malaria.
According to some aspects of the invention, neutralizing epitopes from non-rabies pathogens are inserted into the rabies glycoprotein G in place of rabies glycoprotein G amino acid sequences. Thus, chimeric proteins are formed which are essentially rabies glycoprotein G but which contain neutralizing epitopes from a pathogen antigen inserted within the rabies glycoprotein G protein in place of native rabies glycoprotein sequences. The rabies glycoprotein G sequences provide the necessary sequences to render the chimeric protein orally active. The amino acid sequences that constitute neutralizing epitopes of a pathogen antigen present a target for an immune response which will protect the vaccinated individual from infection by the pathogen.
Those having ordinary skill in the art can readily engineer the nucleic acid sequence that encodes G protein to encode a chimeric protein according to the present invention by routine molecular biology techniques. The amino acid sequence and nucleotide sequence which encode the G protein are disclosed in Anilionis, A. et al . , (1981) Na ture 294:275-278 and Kieny, M.P. et al. (1984) Na ture 312:163, each of which is incorporated herein by reference. Using nucleic acids molecules that encode the G protein as starting material, nucleotides sequences that encode the neutralizing epitopes from other pathogens may be inserted into the G protein coding sequence in place of native G protein nucleotide sequences. The resulting nucleic acid molecule, which encodes a chimeric protein can be used to produce the chimeric protein in well known expression systems such as those which are described above as useful for expressing G protein. The chimeric protein may be routinely isolated for preparation and formulation as an
orally administered pharmaceutical. The isolation, formulation and administration protocols which are described above for isolating, formulating and orally administering the anti-rabies G protein vaccine can be used to in the isolation, formulation and orally administering protocols for anti-pathogen vaccines using the chimeric proteins described herein.
Some embodiments of the present invention relate to compositions for and methods of immunizing a mammal against a pathogen infection comprising the step of orally administering to the mammal a chimeric protein which is a modified rabies glycoprotein G. The chimeric protein contains insertions of 6- 30 amino acids into rabies G protein. The inserted sequences ..omprise an amino acid sequence that constitutes a neutralizing epitope of the pathogen. The insertions are made in place of deletions from the rabies glycoprotein G seσuence between amino acids 20 and 450 of rabies glycoprotein G. In some embodiments, the insertions are made in place of deletions from the rabies glycoprotein G ERA strain. In some embodiments, the insertions are made in place of deletions from the rabies glycoprotein G PM strain. In some embodiments, pharmaceutical compositions are formulated to contain at least 100 μg of the chimeric protein. In methods of the invention, the pharmaceutical composition which contains at least 100 μg of the chimeric protein is administered orally. In some embodiments, pharmaceutical compositions are formulated to contain at least 300 μg of the chimeric protein. In methods of the invention, the pharmaceutical composition which contains at least 300 μg of the chimeric protein is administered orally. In some preferred embodiments, the mammal to be vaccinated is a human. In some preferred embodiments, the pathogen to be targeted is selected form the group set out above as the list of pathogens from which neutralizing epitopes of antigens may be identified. In some preferred embodiments, two or more neutralizing epitopes from the pathogen to be targeted are inserted into the G protein sequence. In some preferred embodiments, two or more neutralizing epitopes from two or more pathogens, respectively, to be targeted are inserted into the
G protein sequence. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 6-25 amino acids. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 8-20 amino acids. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 9-15 amino acids. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 9 amino acids. In some embodiments, the neutralizing epitope is a 6-9 amino acid sequence which is within a 9 ar.ino acid sequence inserted into rabies glycoprotein G at positions 191-198 in place of the rabies G protein sequences. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 20-25 amino acids. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 23 amino acids. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 20- 23 amino acids which is inserted within a 23 amino acid sequences inserted into rabies glycoprotein G at positions 253- 275.
In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 175 and 225 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 185 and 215 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 190 and 205 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies
glycoprotein G sequence between amino acids 191 and 198 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 240 and 295 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 245 and 290 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 250 and 280 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 253 and 275 of the rabies glycoprotein G.
In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 8-25 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 175 and 225 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 9-15 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 185 and 215 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 9-15 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 190 and 205 of the rabies glycoprotein G. In some preferred embc ments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 9 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 191 and 198 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a
neutralizing epitope of the pathogen is 20-25 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 240 and 295 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 20-25 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 245 and 290 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 20-25 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 250 and 280 of the rabies glycoprotein G. In some preferred embodiments, the amino acid sequence that constitutes a neutralizing epitope of the pathogen is 23 amino acids and inserted in place of deletions from the rabies glycoprotein G sequence between amino acids 253 and 275 of the rabies glycoprotein G.
According to the present invention, chimeric proteins may be modified rabies glycoprotein G in which amino acid sequences which define neutralizing epitopes for non-rabies pathogens are inserted in place of G protein sequences. These substitutions are preferably amino acid for amino acid, that is a six amino acid sequence which constitutes a non-rabies neutralizing epitope is inserted into rabies G protein in place of six deleted sequences from rabies G protein. It is contemplated that inserts which contain additional amino acids may be inserted into deletion sites and that inserts which contain fewer amino acids may be inserted into deletion sites. It is also contemplated that portions of the G protein will be deleted without a corresponding insert form a non-rabies pathogen antigen.
In particular, according to some contemplated embodiments, truncated forms of the G protein are linked to amino acid sequences that constitutes a neutralizing epitope of the pathogen. Such fusion proteins contain the portion of the G protein which attaches to the receptor and renders the molecule orally active and an epitope against which an immune
response can be directed to protect against non-rabies infection. As used herein, the term "orally active fragment of G protein" refers to a fragment of the G protein which retains the unexpected ability to be taken up and invoke an immune response when orally administered. When administered orally, orally active fragments of the G protein are able to be presented as immunogenic targets against which an immune response is induced. In some contemplated embodiments, neutralizing epitopes form non-rabies pathogens are linked to orally active fragments of G protein. When administered orally, the portion of the chimeric protein which is an orally active fragment of G protein attaches to cells in the oral cavity and pharynx. An immune response is invoked against the non-rabie: neutralizing epitope of the chimeric protein. According to some aspects of the invention, compositions fcr and methods ofr immunizing a mammal against a pathogen infection are provided. The compositions orally administered to the mammal . The compositions comprise at least 100 μg of isolated rabies glycoprotein G produced in eukaryotic cells and at least 100 μg of a pathogen protein which comprises a neutralizing epitope. In some embodiments, the rabies glycoprotein G and the peptide or protein which comprises the neutralizing epitope of a non-rabies pathogen are unlinked and in some embodiments, the rabies glycoprotein G and the peptide or protein which comprises the neutralizing epitope of a non- rabies pathogen are linked by peptide or non-peptide bonds. When orally administered, the rabies glycoprotein G are taken up by the cells of the oral cavity and pharynx and the peptide or protein which comprises the neutralizing epitope of a non- rabies pathogen, whether linked or unlinked to the rabies G protein is similarly taken up. The amino acid sequences that constitute neutralizing epitopes of a pathogen antigen present a target for an immune response which will protect the vaccinated individual from infection by the pathogen. The rabies glycoprotein G is described above. In some embodiments, the rabies glycoprotein G is from rabies ERA strain. Those having ordinary skill in the art can readily
produce peptides and proteins which comprise an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen. Such amino acid sequences, which induce an immune response against the pathogen which is capable of neutralizing infection by the pathogen, can be readily identified from a pathogen antigen. In some embodiments, the composition comprises a non-rabies pathogen antigen.
In some embodiments, pharmaceutical compositions are formulated to contain at least 100 μg of the rabies G protein and at least 100 μg of the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen. In methods of the invention, the pharmaceutical composition which contains at least 100 μg of the rabies G protein and 100 μg of peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pat_ ogen antigen is administered orally.
In some embodiments, pharmaceutical compositions are formulated to contain at least 300 μg of the rabies G protein and at least 100 μg of the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen. In methods of the invention, the pharmaceutical composition which contains at least 300 μg of the rabies G protein and 100 μg of peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is administered orally.
In some embodiments, pharmaceutical compositions are formulated to contain at least 100 μg of the rabies G protein and at least 300 μg of the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen. In methods of the invention, the pharmaceutical composition which contains at least 100 μg of the rabies G protein and 300 μg of peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is administered orally. In some embodiments, pharmaceutical compositions are formulated to contain at least 300 μg of the rabies G protein and at least 300 μg of the peptide and protein which comprises
an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen. In methods of the invention, the pharmaceutical composition which contains at least 300 μg of the rabies G protein and 300 μg of peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is administered orally.
The compositions and methods of the present invention can be applied to human medical and veterinary medical uses. The present invention relates to compositions and methods of immunizing mammals, particularly humans and bovine, ovine, porcine, equine, canine and feline species. In some preferred embodiments, the mammal to be vaccinated is a human.
In some preferred embodiments, the pathogen to be targeted is selected from the group consisting of those pathogens set out above.
In some embodiments,* the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is linked to the rabies glycoprotein G. In some embodiments, the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is linked to the rabies glycoprotein G by peptide bonds. In some embodiments, the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is linked to the rabies glycoprotein G by non-peptide bonds. In some embodiments, the peptide and protein which comprises an amino ε d sequences that constitutes neutralizing epitopes of a pathogen antigen iε _nked to the rabies glycoprotein G by disulfide bonds. In some embodiments, at least 2, and in some preferred embodiments, multiple copies of the peptide and protein which comprises an amino acid sequences that constitutes neutralizing epitopes of a pathogen antigen is linked to each rabies glycoprotein G molecule.
The compositions of the present invention are useful as components together with other vaccine compositions to form multivalent vaccines. Other components include other orally active vaccine products polio vaccines.
Examples Example 1
The G protein gene of rabies virus ERA strain was recovered from plasmid ptgl55pro8 (Kieny, M.P..,et al . (1984) Na ture 312:163) by digestion with Bgrlll restriction enzyme (Boehringer Mannheim Biochemicals) and subsequently cloned into the unique BamHI site of baculovirus transfer vector pVL941 (Luckow,V.A. and Summers, M.D. (1898) Virology 170:31 which is incorporated herein by reference) . A recombinant plasmid with the G gene in the correct orientation in relation to the polyhedron promoter was obtained and cotransfected with
Au tographa calif ornica nuclear polyhidrosis virus (AcΝPV) DΝA into Spodoptera Frugiperda (Sf9) cells. A recombinant virus
(BVLRG) was selected by limited dilution in combination with dot-blot hybridization and plaque purification, as described (Summers, M.D. and Smith, G.E. 1987 Tex. Agric . Exp . St . Bull . 1555:1 which is incorporated herein by reference) .
To analyze the G protein expressed in the baculovirus system, Sf9 cells grown in a 24-well plate were mock-infected or infected with AcΝPV or the recombinant baculoviruses BVLRG at multiplicity of infection of 10 plaque forming units per cell. At 47 h postinfection, the culture medium was removed and 200 μl methionine-free Grace's medium was added to each well. After incubation for 1 h, the medium was replaced with fresh methionine-free Grace's medium mixed with 30 μCi
[35S] methionine. After incubation for a further 4 h, cells in the wells were harvested, lysed with protein disruption buffer
(2% sodium dodecyl sulphate, 10% glycerol, 5% β- mercaptoethanol, 62.5 mM Tris/HCl, 0.01% bromophenol blue, pH 6.8), and subjected to electrophoresis on a 10% polyacrylamide gel . The gel was then either dried under vacuum and autoradiographed or electrophoretically transferred to nitrocellulose for Western blot analysis. The membrane was blocked with 5% milk powder (Carnation) for 30 min and then incubated with 1/1000 dilution of rabbit anti-rabies G polyclonal antibodies for 1 h. The bound antibody was detected using a peroxidase-conjugated anti-rabbit IgG immunoglobulin
(BMB) . The G protein expressed in Sf9 cells migrated slightly faster on the gels compared to the native G protein of ERA strain of rabies virus. It can also be seen from the pattern of the wild-type AcNPV that there is a protein of the wild-type virus that comigrates with the G protein expressed in Sf9 cells. After the proteins on the gel were transferred to nitrocellulose paper, only the G protein from BVLRG-infected cells and the G protein of rabies virus reacted with rabbit anti-G polyclonal antibodies. Although the G protein expressed in insect cells reacted with the rabbit anti-G polyclonal antisera in the Western blot assay, it was uncertain whether or not the G protein expressed in cells retained its native structure. For this reason, a panel of 41 anti-G monoclonal antibodies (mAb) Wiktor, T.j. and Koprowski, H. (1978) Proc . Na tl Acad . Sci . USA 75:3938; Bunschoten, H. , et al\ (1987) J. Gen . Virol . 70:291; Dietzschold, B.; (1988) Rev. Infect . Dis . 10:S785) , most of which recognize the native form of the G protein, were used for the antigenic analysis of the G protein expressed in Sf9 cells, in comparison with authentic G protein present in rabies virions, using an indirect immunofluorescence test. Sf9 cells and baby hamster kidney (BHK) -21 cells in Terasaki plates
(Nunc) were infected respectively with BVLRG and ERA viruses at a multiplicity of infection of 10. After incubation for 24 h, cells were washed with phosphate-buffered saline, fixed with 80% cold ethanol and incubated with the 41 anti-G mAb. the reaction was detected by fluorescein-conjugated anti-mouse IgG (Cappel) and graded from negative (-) to brilliant fluorescence (++++) . As summarized in Table 1, 33 mAb which reacted vz- th the ERA virus-infected BHK-21 cells infected with ERA rab_.es virus or the Sf9 cells infected with BVLGR. These results indicate that the G protein expressed in insect cells retained its native structure. Example 2 To test the potential for the G protein expressed in
Sf9 cells as -n oral vaccine in raccoons against lethal rabies virus infection, Sf9 cells were infected with BVLRG, harvested
at 60 h poεtinfection and lysed with either 1% Triton X-100 or 1% (β-octylpyranoglucoside. The lysates were then centrifuged at 10 000 g for 20 min and the supernatants were recovered. The concentration of G protein in the supernatant was estimated by SDS-polyacrylamide gel electrophoresis using known amounts of purified rabies virion G protein as standard markers (data not shown) . Eight raccoons were given 1 ml each per os of the lysates containing approximately 100 μg of G protein at day 0 and 200 μg of G protein at 7 weeks. Animals were sedated with ketamine hydrochloride and bled by venipuncture on day 0 and weekly thereafter, as described in Rupprecht, C.E., et al .
(1986) Proc . Na tl Acad . Sci USA 83 :79495. Serum neutralization antibody titers against rabies were determined using a modification of the rapid fluorescent focus-inhibition test, as described by Wiktor et al . 1983 Dev. Biol . Stand . 57:199. Vaccinated animals, as well as controls, were challenged with a street rabies virus and observed for three months after challenge for disease and deaths. Six of the seven immunized raccoons survived the challenge while all of the controls succumbed to rabies and dies within 30 days of challenge (Table 2) .
The results indicate that approximately 300 μg of G protein expressed in insect cells in a crude form can stimulate protective immunity in raccoons against rabies when administered orally. Example 3
The protective effect of oral administration of rabies glycoprotein G isolated from virus particles was determined as follows. The Fix Rabies Virus ERA (The Wistar Institute virus collection, Philadelphia, PA) was propagated on BHK-21 cell monolayers grown at 37°C minimum essential medium supplemented with 10% fetal calf serum. Cell cull supernatants were harvested and inactivated by beta propylactone (BPL) treatment
(1:4000) . The virus suspension was then concentrated and purified by zonal ultracentrifugation on a sucrose gradient. Each purified virus was suspended in phosphate-buffered saline and was adjusted to a protein concentration of 10 micrograms
per microliter. Inactivated virus was purified by adding an equal volume of 4% OGP-NT buffer and incubated for one hour at room temperature. The suspension was centrifuged on a 25% sucrose cushion (NaCl 0.5 M, OGP 2%) in an SW 50 rotor at 12,000 G for 100 minutes at 4°C. The despiculated viral particles were in the sediment. The supernatant was harvested and adjusted to 2.5% sucrose by adding NT buffer. A sucrose gradient was prepared in NaCl 0.5 M, OGP 2% with three layers: one ml at 60% (W/V) , 8 ml of linear gradient 5 to 25% . (W/V) ; and one ml at 3% (W/V) . The glycoprotein suspension was deposited onto the sucrose gradient and centrifuged in a SW 41 rotor at 150,000 G for 36 hours at 4° centigrade. Fractions were harvested in quantities of 0.5 ml from the bottom of the tubes. Fractions which contain glycoproteins are identified. The glycoprotein solution is dialyzed against NT buffer overnight_at 4°C and sterilized by filtration through a .22 μ membrane.
Animals used to test the protective capability of the viral protein consisted of rabies seronegative adult raccoons 1-5 years of age. Prior to handling, all animals were sedated by intramuscular administration of .5 to 1.0 ml of ketamine hydrochloride. Raccoons were given rabies viral G protein per os by needleless syringe: One group of raccoons consisting of six animals was sedated and administered a single 1.0 ml dose of 100 micrograms of ERA rabies G vaccine per os . A second group of raccoons received 1.0 ml of PBS by installation directly into the mouth as a control .
All animals remained healthy throughout the ninety day observation period. In the six raccoons administered 100 micrograms of ERA rabies G vaccine per os , four survived lethal intramuscular challenge on day 90 with 1 x 1055MICLD50/ml of street rabies virus strain MD5951 whereas all six controlled raccoons succumbed. Example 4 The human immunodeficiency viruses (HIVs) are the etiologic agents for acquired immunodeficiency syndrome (AIDS) . Several lines of evidence suggest that the induction of
neutralizing antibodies is a key factor in protective immunity against HIV. The envelope glycoprotein gpl20 (or gpl60) has been the major target for developing candidate vaccines against AIDS since gpl20 recognizes the cellular receptor (CD4) on T lymphocytes and induces neutralizing antibodies. A principal neutralization determinant (PND) has been identified and is located in the third variable domain of the gpl20.
Chimeric genes containing rabies G protein sequences and PND sequences of HIV-1 gpl20 are constructed by replacing linear and/or discontinuous epitopes of rabies virus G protein with PND sequences of HIV-1 gpl20. In some embodiments these chimeric proteins are expressed in mammalian cells via vaccinia virus vectors and in insect cells via baculovirus vectors .
Several lines of evidence suggest that the induction of neutralizing antibodies is a key factor in protective immunity against HIV. Individuals infected by HIV-1 usually develop antibodies that neutralize the virus in vi tro, and neutralization titers seem to decrease with progressive disease, suggesting that the neutralizing antibodies may be protective. Protection experiments have indicated that protection in monkeys against HIV immunized with recombinant envelope proteins correlates with the titers of neutralizing antibodies at the time of challenge. Furthermore monoclonal antibodies which have been shown to neutralize HIVs in vi tro can also protect chimpanzees against challenge infection in vivo . Since most of the neutralizing antibodies are elicited by the envelope protein, most efforts in HIV vaccine development to date have been focused on the envelope glycoprotein. The envelope of HIV-1 is known to contain only two proteins, the exterior surface glycoprotein' of 120 kDa
(gpl20) and the transmembrane protein of 41 kDa (gp41) , both of which are derived from a common precursor, gpl60. It was shown that recombinant proteins or viruses, like the native proteins purified from HIV-infected cells, induced high levels of HIV- specific antibodies, some with neutralizing activity, in experimental animals or human volunteers. Immunization of monkeys with the recombinant proteins purified from CHO cells
have resulted in the induction of neutralizing antibodies and some of the immunized monkeys with high neutralizing antibody titers were protected against a challenge infection with homologous virus strain. Most of the neutralizing antibodies elicited by recombinant envelope proteins in t 3t animals have been mapped to the central portion of gpl20 (amino acids 307 to 338) since these antibodies can be absorbed with synthetic peptides derived from this region. Furthermore, similar peptide was found to absorb substantial fractions of neutralizing antibodies in sera from HIV-1 infected people. All these peptides are within a disulfide-linked loop in the third variable domain (V3 loop) of gpl20. This principal neutralizing determinant (PND) is one of the more variable regions of the envelope and differs by as much as 50% among HIV isolates which explains whyfc the neutralizing antibodies stimulated by recombinant envelope proteins are type-specific. Neutralization antib .ies elicited by synthetic peptides derived from PND have also been shown to be strain-specific. However, recent sequence analysis of many HIV isolates from
North America and Europe revealed that sequence in the central portion of V3 loop, GPGRAF (SEQ ID NO: 1) , is relatively conserved although the sequences flanking the GPGRAF (SEQ ID NO: 1) regions in these isolates may be different. Over 65% of HIV-1 positive sera reacted with peptides containing this sequence. Furthermore, antisera from rabbits immunized with a peptide containing the GPGRAF (SEQ ID NO: 1) residues neutralized divergent isolates such as IIIB and MN. Monoclonal antibodies selected against the PND have been shown to neutralize Hi infectivity in vi tro and to protect chimpanzees against HIV challenge infection in vivo .
The data summarized above demonstrate that subunit vaccines such as the envelope proteins (gpl20 and gplδO) or peptides derived from it can stimulate the production of neutralizing antibodies in immunized animals or humans. The results obtained from immunized monkeys also show that vaccination with these subunit vaccines can also protect
against infection if the neutralizing antibcdy titers are high enough at the time of challenge. The peptide vaccines derived from PND may have some advantages over the entire envelope protein since some antibodies to the envelope protein but not to the PND have been shown to enhance HIV infectivity in vi tro although this has not been reported in vivc
More research should be directed to develop vaccines to induce local mucosal immunity. One way to stimulate local immune responses is by oral immunization. Oral vaccination not only stimulates IgA precursor B cells in the gut-associated lymphoid tissues but also leads to the dissemination of B and T cells to other mucosal effector tissues including genital tracts for subsequent antigen-specific S-IgA antibody production. In one embodiment of the present invention rabies virus glycoprotein 'is used as a vehicle to target HIV antigens to the pregastric mucous membrane since rabies virus G protein is a superb oral immunogen and can induce systemic immune responses when given orally. Although the local immune responses to the rabies virus G protein have not been investigated, it is believed that it can also stimulate local immune responses. A linear neutralizing epitope has been defined on the G protein and immunization with a peptide derived from this epitope resulted in the production of neutralizing antibodies and protected mice against lethal challenge, which provide the sites to engineer HIV epitopes. We have also identified an epitope at antigenic site II of rabies virus G protein by computer modeling. Epitopes of rabies G protein are replaced with HIV PND epitopes from MN- like strain since MN-like strains are the most prevalent in both North America and Europe and peptides derived from PND of these strains can induce broadly neutralizing antibodies. The chimeric protein will be expressed either in insect cells via baculovirus or in mammalian cells by vaccinia viruses and then studied for its antigenicity and immunogenicity.
To confirm that rabies virus glycoprotein is a good oral immunogen, we have expressed the glycoprotein in a
baculovirus expression system and studied its oral immunogenicity. To express rabies virus G protein, the G protein gene of rabies virus ERA strain was recovered from plasmid ptg 155pro8 by digestion with Bglll restriction enzyme and cloned into the unique BamHI site of a baculovirus transfer vector pVL941. After cotransfection of the recombinant plasmid and wide type baculovirus DNA into Sf9 cells, the recombinant baculovirus containing the rabies virus G protein was selected. It was found that the recombinant virus expressed the G protein abundantly -in insect cells which was recognized by rabbit anti- rabies G polyclonal antibodies in a Western blot assay. The G protein expressed in insect cells retained its native structure as shown by immunofluorescent antibody test that the G protein expressed in insect cells reacted with 33 out of 41 monoclonal antibodies to the G protein. When lysates extracted from insect cells expressing the G protein with either 1% Triton X-
100 or 1% b-octyl pyranoglucoside was given to raccoons per os
(approximately 100 mg of G protein at day 0 and 200 mg of G protein at 7 weeks) , all seven animals immunized produced neutralizing antibodies and six of them survived lethal challenge with street rabies virus while all of the seven control raccoons succumbed to rabies and died within 30 days of challenge. These data demonstrated that rabies virus G protein is a good oral immunogen and can induce neutralizing antibodies and protect immunized animals against lethal challenge when given orally.
In order to make chimeric rabies virus G protein containing HIV PND, we have used computer modeling to identify potential sites on rabies G protein to insert HIV PND sequences. It is found that amino acid residues 191 to 198, which is located in antigenic site II of the rabies G protein, is a good site for engineering HIV PND sequence. To replace amino acids 191 to 198 of rabies G protein, IFTNSRGKR (SEQ ID NO: 2) , with HIV PND sequence IHIGPGRAF (SEQ ID NO: 3) , site directed mutagenesis by overlapping PCR was performed with four synthetic oligonucleotides . SEQ ID NO: 4 is the 5' end of rabies G protein with the incorporation of a Bglll site and
oligonucleotide number 4 is near the 3' end of rabies G protein with the incorporation of a Clal site. SEQ ID NOS: 5 and 6 represent the site for mutation, each has 15 nucleotides for basepairing and 27 nucleotides (coding the changed 9 amino acids) overhang. In the initial step, PCR was performed with SEQ ID NOS: 4 and 5 or SEQ ID NOS: 6 and 7 using ptgl55pro8 as template. A Fragment with 0.7 kb was obtained with SEQ ID NOS: 6 and 7 and another fragment with 1.0 kb was obtained with SEQ ID NOS: 6 and 7. The corresponding fragments were collected and purified with GeneClean (Bio 101) , and finally used as templates to amplify the complete chimeric gene with SEQ ID NO 7. As expected, a fragment with 1.7 kb was synthesized and this fragment will be cloned into vaccinia virus or baculovirus transfer vectors.
Oligo 1: ACTGGCAAGATCTAATATGGTTCCTCAG (SEQ ID NO:4)
Oligo 2: AAACGCTCTCCCAGGCCCAATGTGAATGTCACAAGACATCCC (SEQ ID
NO:5)
Oligo 3: ATTCACATTGGGCCTGGGAGAGCGTTTGCATCCAAAGGGAGT (SEQ ID
NO: 6) Oligo 4: GCGTAGGTTCTGATCGATTGACTCTTC (SEQ ID NO:7)
HIV antigens are targeted to the pregastric mucous membrane using rabies virus G protein as a delivering vehicle. The chimeric genes are constructed and expressed (rabies G-HIV PND) in vaccinia virus or baculoviruses. Construction of chimeric gene at the discontinuous epitope site is performed as follows. As described above, the chimeric gene amplified by overlapping PCR is digested with Bglll and Clal and cloned into ptgl55pro8 also digested with the same enzymes. Alter ligation and transformation, the chimeric gene is sequenced using the primer extension method to make sure that the amplified gene has the correct HIV PND seσuence in frame. The chimeric gene in the resulting clone has the complete coding sequence for rabies virus G protein within two Bglll sites as the original ptgl55pro8.
Construction of chimeric genes at the linear epitope site is performed as follows. A linear epitope was mapped to residue 253 to 275 (23 residues) of the rabies virus G protein by MAb 6-15C4, which provides a site for replacement with sequence derived from HIV PND. This epitope is located between two restriction enzyme sites on the rabies virus G protein gene, with BanI at the 5' end and Aatll at the 3' end. Two chimeric genes are constructed at this site. First, this epitope on rabies G protein (23 amino acids) is replaced by exact 23 amino acids derived from the PND of HIV MN strain.
The 23 amino acids on rabies G protein PPDQLVNLHDFRSDEIEHLWEE
(SEQ ID NO: 8) is replaced with 23 amino acids from the PND of
MN strain YNKRKRIHIGPGRAFYTTKNIIG (SEQ ID NO: 9) . To accomplish this, two synthetic oligonucleotides (SEQ ID NO: 10 and SEQ ID NO:ll) with restriction sites at each end, BanI at the 5' end and Aatll at the 3' end are use These oligonucleotides will be annealed and phosphorylated, which is then cloned into ptgl55pro8 digested with BanI and Aatll.
GTGCTATAACAAACGCAAGCGGATTCACATCGGGCCTGGGAGAGCCTTCTATACGACCAAA AATATAATAGGGTTGGTCAGGAAGAGAGAGGAGTGTCTGGATGCACTAGAGTCCATCATGA CAACCAAGTCAGTGAGTTTCAG (SEQ ID NO: 10)
ACGTCTGAAACTCACTGACTTGGTTGTCATGATGGACTCTAGTGCATCCAGACACTCCTCT TCTTCCTGACCAACCCTATTATATTTTTGGTCGTATAGAAGGCTCTCCCAGGCCCGATGT GAATCCGCTTGCGTTTGTTATA (SEQ ID NO:11)
Second, the linear epitope on rabies G protein s reolaced by the whole V3 loop. The sequence
I ?LVNLHDFRSDEIEHLWEELVRLRDDCLDAL (SEQ ID NO:12) of rabies s G protei is replaced with the sequence of V3 loop of
1 MN stra-L.t CTRPNYNKRKRIHIGPGRAFYTTKNIIGTMRQAHC (SEQ ID 1% .13) . Again th s is carried out with synthetic oligonucleotides (SEQ .D NO:: =ιnd £" ~ ID NO:15) with the same restriction sites as describe. abov_
GTGCTGTACCAGGCCTAACTATAACAAGAGAAAGAGAATTCACATTGGGCCTGGGAGAGCC TTCTATACCACTAAGAACATTATAGGGACCATAAGACAAGCCCACTGTGAGTCCATCATGA CAACCAAGTCAGTGAGTTTCAG (SEQ ID NO: 14)
ACGTCTGAAACTCACTGACTTGGTTGTCATGATGGACTCACAGTGGGCTTGTCTTATGGTC CCTATAATGTTCTTAGTGGTATAGAAGGCTCTCCCAGGCCCAATGTGAATTCTCTTTCTCT TGTTATAGTTAGGCCTGGTACA3 (SEQ ID NO:15)
The chimeric genes are transformed and clones with the correct mutagenesis are selected for -cloning into baculovirus or vaccinia virus transfer vectors. Expression o£ chimeric genes by vaccinia virus vectors is accomplished as follows. To express these chimeric genes in vaccinia virus, the protocol used to express rabies virus G protein in vaccinia virus are followed. The chimeric genes described above are digested with Bglll and cloned into the unique BamHI site of ptglH-Tk-P7.5. The resulting clones are screened and sequenced to select those clones with the chimeric genes in the correct orientation, which are then co-transfected with wild type vaccinia virus (Copenhagen strain) into HeLa fibroblasts. HeLa cells are infected with wide type vaccinia virus two hours before recombinant plasmids are transfected.
Recombinant vaccinia virus expressing these chimeric proteins are selected by infecting TK" 143 osteosarcoma cells in the presence of 5-bromodeoxyuridine (BrdUrd) . To make sure that recombinant vaccinia viruses express the correct proteins, virus eluted from plaques selected in TH" cells are used to infect HeLa cells in 6-well plates at the multiplicity of infection (moi) of 10 plaque forming units (pfu) per cell. Four hours after infection, cells are harvested and lysed with protein disruption buffer (2% ΞDS, 10% glycerol, 5% b- mercaptoethanol, 62.5 mM Tris-HCl, 0.01% bromphenol blue, pH
6.8) . Alter electrophoresis on 10% SDS-PAGE, proteins are electrotransferred to nitrocellulose paper and reacted with rabbit anti-G polyconoal antibodies against rabies virus G protein, monoclonal antibody to the V3 loops of MN strain. To verify that these chimeric proteins expressed by these
recombinant vaccinia viruses retain the native structure of rabies virus G protein and expressed on the cell surface, immunofluorescence antibody assays are used with monoclonal antibodies recognizing the native rabies virus G protein. In all these assays, recombinant vaccinia viruses expressing rabies glycoprotein and recombinant vaccinia virus expressing HIV gpl60 are included as positive controls.
The chimeric genes are expressed in insect cells via baculovirus vectors as follows. To express these chimeric proteins in insect-cells via baculovirus vectors, the chimeric genes are digested with Bglll and cloned into the unique BamHI site of pVL941. The resulting clones are screened and sequenced to select one clone with the chimeric gene in the correct orientation in relation to the polyhedron promoter, which will then be co-transfected with AcNPV DNA into Sf9 cells. The method of limited dilution, combined with DNA dot- blot hybridization is used to detect and select recombinant baculovirus containing these chimeric genes. The recombinant baculoviruses are purified by plaque purification and used for the production of recombinant baculovirus stocks. The recombinant baculoviruses containing these chimeric genes are used to infect Sf9 cells in a 6-well plate at moi of approximately 10 pfu per cell. Infected cells are harvested at 60 hours post infection, lysed with protein disruption buffer and subjected to electrophoresis on a 10% polyacrylamide gel containing SDS. Proteins separated on the gel are electrotransferred to nitrocellulose paper and reacted with antibodies to rabies virus G protein, antibodies to V3 loop of MN strain, or sera from HIV-positive patients. Immunofluorescent antibody assays are also used to make sure that the chimeric G proteins expressed in insect cells retain its native structure. Rabies virus G protein expressed in insect cells and gpl60 of HIV are included as positive controls .
TABLE I
SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: Fu, Zhen Fang
Rupprecht, Charles E.
(ii) TITLE OF INVENTION: Oral Vaccination of Mammals
(iii) NUMBER OF SEQUENCES: 15
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & Norris
(B) STREET: One Liberty Place, 46th Floor
(C) CITY: Philadelphia
(D) STATE: Pennsylvania
(E) COUNTRY: USA
(F) ZIP: 19103
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: WordPerfect 5.1
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
(vi) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: 08/129,654
(B) FILING DATE: 30-SEP-1993
(C) CLASSIFICATION:
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: DeLuca, Mark
(B) REGISTRATION NUMBER: 33,229
(C) REFERENCE/DOCKET NUMBER: TJU-1334
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 215-568-3100
(B) TELEFAX: 215-568-3439
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1 :
Gly Pro Gly Arg Ala Phe 1 5
(2) INFORMATION FOR SEQ ID NO:2 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 : lie Phe Thr Asn Ser Arg Gly Lys Arg 1 5
(2) INFORMATION FOR SEQ ID NO:3 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 9 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3 : lie His lie Gly Pro Gly Arg Ala Phe 1 5
(2) INFORMATION FOR SEQ ID NO:4 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 28 base pairs
(B) TYPE: nucleic acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID N0:4:
ACTGGCAAGA TCTAATATGG TTCCTCAG 28
(2) INFORMATION FOR SEQ ID NO: 5 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid >_ (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5 :
AAACGCTCTC CCAGGCCCAA TGTGAATGTC ACAAGACATC CC 42
(2) INFORMATION FOR SEQ ID NO:6 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6 :
ATTCACATTG GGCCTGGGAG AGCGTTTGCA TCCAAAGGGA GT 42
(2) INFORMATION FOR SEQ ID NO:7 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 27 base pairs
(B) TYPE: nucleic acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7 :
GCGTAGGTTC TGATC^.TTG ACTCTTC 27
(2) INFORMATION FOR SEQ ID NO:8:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8 :
Pro Pro Asp Gin Leu Val Asn Leu His Asp Ph<Ξ Arg Ser Asp Glu lie 1 5 10 15
Glu His Leu Val Val Glu Glu 20
(2) INFORMATION FOR SEQ ID NO:9:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 23 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9 :
Tyr Asn Lys Arg Lys Arg lie His lie Gly Pro Gly Arg Ala Phe Tyr 1 5 10 15
Thr Thr Lys Asn lie lie Gly 20
(2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 144 base pairs
(B) TYPE: nucleic acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:
GTGCTATAAC AAACGCAAGC GGATTCACAT CGGGCCTGGG AGAGCCTTCT ATACGACCAA 60
AAATATAATA GGGTTGGTCA GGAAGAGAGA GGAGTGTCTG GATGCACTAG AGTCCATCAT 120
GACAACCAAG TCAGTGAGTT TCAG 144
(2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 144 base pairs
(B) TYPE: nucleic acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: CDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:
ACGTCTGAAA CTCACTGACT TGGTTGTCAT GATGGACTCT AGTGCATCCA GACACTCCTC 60
TCTCTTCCTG ACCAACCCTA TTATATTTTT GGTCGTATAG AAGGCTCTCC CAGGCCCGAT 120
GTGAATCCGC TTGCGTTTGT TATA 144
(2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12 :
Pro Pro Asp Gin Leu Val Asn Leu His Asp Phe Arg Ser Asp Glu lie 1 5 10 15
Gle His Leu Val Val Glu Glu Leu Val Arg Leu Arg Asp Asp Cys Leu 20 25 30
Asp Ala Leu 35
(2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 35 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: peptide
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:
Cys Thr Arg Pro Asn Tyr ' -n Lys Arg Lys Arg lie His lie Gly Pro 1 5 10 15
Gly Arg Ala Phe Tyr Thr Thr Lys Asn lie lie Gly Tyr Met Arg Gin 20 25 30
Ala His Cys 35
(2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 144 base pairs
(B) TYPE: nucleic acid (D) TOPOLOGY: linear
(ii) MOLEC" Ξ TYPE: cDNA
(xi) SEQUE. E DESCRIPTION: SEQ ID NO:14 :
GTGCTGTACC AGGCCTAACT ATAACAAGAG AAAGAGAATT CACATTGGGC CTGGGAGAGC 60
CTTCTATACC ACTAAGAACA TTATAGGGAC CATAAGACAA GCCCACTGTG AGTCCATCAT 120
GACAACCAAG TCAGTGAGTT TCAG 144
(2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 144 base pairs
(B) TYPE: nucleic acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: cDNA
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:
ACGTCTGAAA CTCACTGACT TGGTTGTCAT GATGGACTCA CAGTGGGCTT GTCTTATGGT 60
CCCTATAATG TTCTTAGTGG TATAGAAGGC TCTCCCAGGC CCAATGTGAA TTCTCTTTCT 120
CTTGTTATAG TTAGGCCTGG TACA 144
Claims
1. An oral anti-rabies vaccine comprising at least 100 μg of an isolated rabies glycoprotein G that is produced in eukaryotic cells; and an carrier suitable for oral administration.
2. The oral anti-rabies vaccine of claim 1 comprising at least 300 μg of said isolated rabies glycoprotein G.
3. The oral anti-rabies vaccine of claim 1 wherein said isolated rabies glycoprotein G is produced in a baculovirus expression system.
4. The oral anti-rabies vaccine of claim 1 wherein said isolated rabies glycoprotein G is part of an encapsulated composition.
5. The oral anti-rabies vaccine of claim 1 further comprising food.
6. A method of immunizing a mammal against rabies infection comprising the step of orally administering to said mammal the oral anti-rabies vaccine of claim 1.
7. The method of claim 6 wherein said mammal is a raccoon.
8. The method of claim 6 wherein said isolated rabies glycoprotein G is produced in a baculovirus expression system.
9. The method of claim 6 wherein said isolated rabies glycoprotein G is administered as an encapsulated composition.
10. The method of claim 6 wherein said mammal is administered at least 300 μg of isolated rabies glycoprotein G.
11. A chimeric protein that is a modified rabies glycoprotein G comprising native rabies glycoprotein G amino acid sequence except wit:: a 6-30 amino acid sequence substitution between amino acids 20 and 450 of said rabies glycoprotein G amino acid sequence, said 6-30 amino acid substitution comprising an amino acid sequence that constitutes a neutralizing epitope of a pathogen.
12. The chimeric protein of claim 11 wherein said 6-30 amino acid substitution is between amino acids 175-225 of said rabies glycoprotein G.
13. The chimeric protein of claim 11 wherein said 6-30 amino acid s', ^stitution is between amino acids 150-275 of said rabies glycoprotein G.
14. The chimeric protein of claim 11 wherein said 6-30 amino acid substitution is a 9 am„-o acid substitution.
15. The chimeric protein of claim 14 wherein said 9 amino acid substitution is between amino acids 191-198 of said rabies glycoprotein G.
16. The chimeric protein of claim 11 wherein said 6-30 amino acid substitution is a 23 amino acid substitution.
17. The chimeric protein of claim 16 wherein said 23 amino acid substitution is between amino acids 253-275 of said rabies glycoprotein G.
18. An orally active vaccine for immur-.ιzing a mammal against a pathogen infection comprising a chimeric protein of claim 11.
19. A method of immunizing a mammal against a pathogen infection comprising the step of orally administering to said mammal at least 100 μg of a chimeric protein of claim 11.
20. The method'bf claim 19 wherein said mammal is a human.
21. The method of claim 19 wherein at least 300 μg of said chimeric protein is orally administering to said mammal .
22. An oral anti-pathogen vaccine comprising at least 100 μg of an isolated rabies glycoprotein G that is produced in eukaryotic cells; at least 100 μg of an isolated pathogen antigen or a peptide which comprises an amino acid sequence that constitutes a neutralizing epitope of said pathogen; and an carrier suitable for oral administration.
23. The oral anti-pathogen vaccine of claim 22 comprising at least 300 μg of said isolated rabies glycoprotein G.
24. The oral anti-pathogen vaccine of claim 22 comprising at least 300 μg of an isolated pathogen antigen or a peptide which comprises an amino acid sequence that constitutes a neutralizing epitope of said pathogen.
25. The oral anti-pathogen vaccine of claim 22 comprising at least 300 μg of said isolated rabies glycoprotein G and at least 300 μg of an isolated pathogen antigen or a peptide which comprises an amino acid sequence that constitutes a neutralizing epitope of said pathogen.
26. The oral anti-pathogen vaccine of claim 22 wherein said isolated rabies glycoprotein G is produced in a baculovirus expression system.
27. The oral anti-pathogen vaccine of claim 22 comprising at least 100 μg of an isolated rabies glycoprotein G that is produced in eukaryotic cells; at least 100 μg of an isolated pathogen antigen; and an carrier suitable for oral administration.
28. The oral anti-pathogen vaccine of claim 27 wherein said isolated rabies glycoprotein G is covalently linked to said isolated pathogen antigen.
29. The oral anti-pathogen vaccine of claim 22 comprising at least 100 μg of an isolated rabies glycoprotein G that is produced in eukaryotic cells; at least 100 μg of a peptide which comprises an amino acid sequence that constitutes a neutralizing epitope of said pathogen; and a carrier suitable for oral administration.
30. The oral anti-pathogen vaccine of claim 27 wherein said isolated rabies glycoprotein G is covalently linked to said peptide which comprises an amino acid sequence that constitutes a neutralizing epitope of said pathogen.
31. A method of immunizing a mammal against a pathogen infection comprising the step of orally administering to said mammal the oral anti-pathogen vaccine of claim 27 .
32. The method of claim 31 wherein said mammal is a human.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU78470/94A AU7847094A (en) | 1993-09-30 | 1994-09-30 | Oral vaccination of mammals |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12965493A | 1993-09-30 | 1993-09-30 | |
US08/129,654 | 1993-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995009249A1 true WO1995009249A1 (en) | 1995-04-06 |
Family
ID=22440983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/011112 WO1995009249A1 (en) | 1993-09-30 | 1994-09-30 | Oral vaccination of mammals |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU7847094A (en) |
WO (1) | WO1995009249A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6673601B1 (en) * | 1999-04-15 | 2004-01-06 | Institut Pasteur | Chimeric lyssavirus nucleic acids and polypeptides |
WO2006084006A1 (en) * | 2005-02-02 | 2006-08-10 | University Of Massachusetts | Human antibodies against rabies and uses thereof |
US7238672B1 (en) | 2000-04-17 | 2007-07-03 | Institut Pasteur | Chimeric lyssavirus nucleic acids and polypeptides |
US7863041B2 (en) | 2005-10-14 | 2011-01-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Rabies virus vector systems and compositions and methods thereof |
US7901691B2 (en) * | 2004-08-13 | 2011-03-08 | Council Of Scientific And Indistrial Research | Chimeric G protein based rabies vaccine |
US8846051B2 (en) | 2004-10-08 | 2014-09-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by deoptimization of synonymous codons |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985001516A1 (en) * | 1983-10-03 | 1985-04-11 | Transgene S.A. | Vectors for the expression of an antigenic protein of rabies in eucaryotic cells and application thereof to the preparation of a vaccine |
US4650673A (en) * | 1985-09-06 | 1987-03-17 | Connaught Laboratories Limited | Oral immunization of mammals |
US4707356A (en) * | 1985-07-03 | 1987-11-17 | The Salk Institute For Biological Studies | Synthetic peptide-based anti-rabies compositions and methods |
US5008373A (en) * | 1986-11-01 | 1991-04-16 | Oxford Gene Systems Limited | Fusion proteins and particles |
US5169784A (en) * | 1990-09-17 | 1992-12-08 | The Texas A & M University System | Baculovirus dual promoter expression vector |
US5266313A (en) * | 1987-02-03 | 1993-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms |
US5348741A (en) * | 1987-02-03 | 1994-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Vector for recombinant poxvirus expressing rabies virus glycoprotein |
-
1994
- 1994-09-30 WO PCT/US1994/011112 patent/WO1995009249A1/en active Application Filing
- 1994-09-30 AU AU78470/94A patent/AU7847094A/en not_active Abandoned
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1985001516A1 (en) * | 1983-10-03 | 1985-04-11 | Transgene S.A. | Vectors for the expression of an antigenic protein of rabies in eucaryotic cells and application thereof to the preparation of a vaccine |
US4707356A (en) * | 1985-07-03 | 1987-11-17 | The Salk Institute For Biological Studies | Synthetic peptide-based anti-rabies compositions and methods |
US4650673A (en) * | 1985-09-06 | 1987-03-17 | Connaught Laboratories Limited | Oral immunization of mammals |
US5008373A (en) * | 1986-11-01 | 1991-04-16 | Oxford Gene Systems Limited | Fusion proteins and particles |
US5266313A (en) * | 1987-02-03 | 1993-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Raccoon poxvirus as a gene expression and vaccine vector for genes of rabies virus and other organisms |
US5348741A (en) * | 1987-02-03 | 1994-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | Vector for recombinant poxvirus expressing rabies virus glycoprotein |
US5169784A (en) * | 1990-09-17 | 1992-12-08 | The Texas A & M University System | Baculovirus dual promoter expression vector |
Non-Patent Citations (11)
Title |
---|
G.M. BAER, "The Natural History of Rabies", Second Edition, Published 1991, by CRC PRESS (BOCA RATON, FLORIDA), pages 485-503. * |
J. GEN. VIROL., Volume 40, issued 1978, B. DIETZSCHOLD et al., "Isolation and Purification of a Polymeric form of the Glycoprotein of Rabies Virus", pages 131-139. * |
J. WILDLIFE DISEASES, Volume 28, Number 4, issued 1992, C.E. RUPPRECHT et al., "Consideration of Inactivated Rabies Vaccines as Oral Immunogens of Wild Carnivores", pages 629-635. * |
NATURE, Volume 322, issued 24 July 1986, J. BLANCOU et al., "Oral Vaccination of the Fox Against Rabies Using a Live Recombinant Vaccinia Virus", pages 373-375. * |
PROC. NATL. ACAD. SCI. U.S.A., Volume 81, issued November 1984, T.J. WIKTOR et al., "Protein from Rabies by a Vaccinia Virus Recombinant Containing the Rabies Virus Glycoprotein Gene", pages 7194-7198. * |
PROC. NATL. ACAD. SCI. U.S.A., Volume 83, issued October 1986, C.E. RUPPRECHT et al., "Oral Immunization and Protection of Raccoons (Procyon Lotor) with a Vaccinia-rabies Glycoprotein Recombinant Virus Vaccine", pages 7947-7950. * |
PROC. NATL. ACAD. SCI. U.S.A., Volume 84, issued December 1987, B. DIETZSCHOLD et al., "Induction of Protective Immunity Against Rabies by Immunization with Rabies Virus Ribonucleoprotein", pages 9165-9169. * |
REVIEWS OF INFECTIOUS DISEASES, Volume 10, Supplement 4, issued November-December 1988, C.E. RUPPRECHT et al., "Efficacy of a Vaccinia-Rabies Glycoprotein Recombinant Virus Vaccine in Raccoons (Procyon Lotor)", pages S803-S809. * |
REVIEWS OF INFECTIOUS DISEASES, Volume 10, Supplement 4, issued November-December 1988, G.M. BAER, "Oral Rabies Vaccination: An Overview", pages S644-S648. * |
VIROLOGY, Volume 165, Number 1, issued 1988, J.J. ESPOSITO et al., "Successful Oral Rabies Vaccination of Raccoons with Raccoon Poxvirus Recombinants Expressing Rabies Virus Glycoprotein", pages 313-316. * |
VIROLOGY, Volume 173, issued 1989, C. PREHAUD et al., "Immunogenic and Protective Properties of Rabies Virus Glycoprotein Expressed by Baculovirus Vectors", pages 390-399. * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6673601B1 (en) * | 1999-04-15 | 2004-01-06 | Institut Pasteur | Chimeric lyssavirus nucleic acids and polypeptides |
US7235245B2 (en) | 1999-04-15 | 2007-06-26 | Institut Pasteur | Chimeric lyssavirus nucleic acids and polypeptides |
US7645455B2 (en) | 1999-04-15 | 2010-01-12 | Institut Pasteur | Chimeric lyssavirus nucleic acids and polypeptides |
US7238672B1 (en) | 2000-04-17 | 2007-07-03 | Institut Pasteur | Chimeric lyssavirus nucleic acids and polypeptides |
US7901691B2 (en) * | 2004-08-13 | 2011-03-08 | Council Of Scientific And Indistrial Research | Chimeric G protein based rabies vaccine |
US8846051B2 (en) | 2004-10-08 | 2014-09-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by deoptimization of synonymous codons |
US10695414B2 (en) | 2004-10-08 | 2020-06-30 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Center For Disease Control And Prevention | Modulation of replicative fitness by deoptimization of synonymous codons |
US11497803B2 (en) | 2004-10-08 | 2022-11-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Modulation of replicative fitness by deoptimization of synonymous codons |
US7727532B2 (en) | 2005-02-02 | 2010-06-01 | University Of Massachusetts | Human antibodies against rabies and uses thereof |
US8226952B2 (en) | 2005-02-02 | 2012-07-24 | University Of Massachusetts | Human antibodies against rabies and uses thereof |
WO2006084006A1 (en) * | 2005-02-02 | 2006-08-10 | University Of Massachusetts | Human antibodies against rabies and uses thereof |
US7863041B2 (en) | 2005-10-14 | 2011-01-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Rabies virus vector systems and compositions and methods thereof |
US8865461B2 (en) | 2005-10-14 | 2014-10-21 | The United States of America as represtented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention | Rabies virus vector systems and compositions and methods thereof |
Also Published As
Publication number | Publication date |
---|---|
AU7847094A (en) | 1995-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5591823A (en) | Expression of specific immunogens using viral antigens | |
FI110438B (en) | A method of producing mutant herpesvirus | |
JP3972218B2 (en) | Recombinant live vaccine based on feline herpesvirus type 1 especially for infectious feline peritonitis | |
EP0349594A1 (en) | Recombinant baculovirus occlusion bodies in vaccines and biological insecticides | |
US6020309A (en) | Pharmaceuticals based on papillomaviruses | |
HU214904B (en) | Process for producing of recombinant herpesvirus os turkeys and live vector vaccines derived thereof | |
EP0405867A1 (en) | Novel compounds | |
CA2134898A1 (en) | Compositions and methods for vaccination against coronaviruses | |
US5443828A (en) | Chimeric HIV-2 gag particles | |
Tami et al. | Presentation of antigenic sites from foot-and-mouth disease virus on the surface of baculovirus and in the membrane of infected cells | |
CN113862284B (en) | Gene, virus-like particle, vaccine and preparation and application for encoding recombinant avian influenza virus HA protein | |
EP0651806B1 (en) | Anti-feline immunodeficiency virus (fiv) vaccines | |
WO1995009249A1 (en) | Oral vaccination of mammals | |
KR101370817B1 (en) | Hiv vaccine | |
JP3447743B2 (en) | Non-splicing variants of gp350 / 220 | |
US6673601B1 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
US6458362B1 (en) | Recombinant VP2 parvoviral pseudo-particles encoding CTL or T-helper cell epitopes | |
EP0595970A1 (en) | Improved vaccine | |
EP0606452A1 (en) | Vector vaccines of recombinant feline herpesvirus | |
US7238672B1 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
JP4317912B2 (en) | AIDS vaccine | |
CN115845042A (en) | Recombinant novel coronavirus S protein trimer vaccine composition and application thereof | |
CA1325610C (en) | Recombinant baculovirus occlusion bodies in vaccines and biological insecticides | |
EP1721982B1 (en) | Chimeric lyssavirus nucleic acids and polypeptides | |
AU2366592A (en) | Improved vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |